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ABSTRACT 
Steven Paul Moberly 
IMPAIRED CARDIOVASCULAR RESPONSES TO GLUCAGON-LIKE PEPTIDE 
1 IN METABOLIC SYNDROME AND TYPE 2 DIABETES MELLITUS 
 
Recent advancements in the management of systemic glucose regulation 
in obesity/T2DM include drug therapies designed to utilize components of the 
incretin system specifically related to glucagon-like peptide 1 (GLP-1). More 
recently, GLP-1 has been investigated for potential cardioprotective effects. 
Several investigations have revealed that acute/sub-acute intravenous 
administration of GLP-1 significantly reduces myocardial infarct size following 
ischemia/reperfusion injury and improves cardiac contractile function in the 
settings of coronary artery disease, myocardial ischemia/reperfusion injury, and 
heart failure. Despite an abundance of data indicating that intravenous infusion of 
GLP-1 is cardioprotective, information has been lacking on the cardiac effects of 
iv GLP-1 in the MetS or T2DM population. Some important questions this study 
aimed to address are 1) what are the direct, dose-dependent cardiac effects of 
GLP-1 in-vivo 2) are the cardiac effects influenced by cardiac demand (MVO2) 
and/or ischemia, 3) does GLP-1 effect myocardial blood flow, glucose uptake or 
total oxidative metabolism in human subjects, and 4) are the cardiac effects of 
GLP-1 treatment impaired in the settings of obesity/MetS and T2DM. Initial 
studies conducted in canines demonstrated that GLP-1 had no direct effect on 
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coronary blood flow in-vivo or vasomotor tone in-vitro, but preferentially 
increased myocardial glucose uptake in ischemic myocardium independent of 
effects on cardiac contractile function or coronary blood flow. Parallel 
translational studies conducted in the humans and Ossabaw swine demonstrate 
that iv GLP-1 significantly increases myocardial glucose uptake at rest and in 
response to increases in cardiac demand (MVO2) in lean subjects, but not in the 
settings of obesity/MetS and T2DM. Further investigation in isolated cardiac 
tissue from lean and obese/MetS swine indicate that this impairment in GLP-1 
responsiveness is related to attenuated activation of p38-MAPK, independent of 
alterations in GLP-1 receptor expression or PKA-dependent signaling. Our 
results indicate that the affects of GLP-1 to reduce cardiac damage and increase 
left ventricular performance may be impaired by obesity/MetS and T2DM. 
 
Johnathan D. Tune, Ph.D., Chair 
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Chapter 1 
Diabetes Mellitus, Metabolic Syndrome and Cardiovascular Disease 
An increasing prevalence of Type 2 Diabetes Mellitus (T2DM) is a major 
national and global health concern with several important implications. The 
impact of this disease not only burdens our societies with morbidity and mortality, 
but also carries a large demand for structural, social and economic support. It is 
estimated that close to 350 million people worldwide have Diabetes Mellitus (1), 
and that over 8.3% of the United States population has this disease (2). T2DM 
typically accounts for approximately 90-95% of these cases (2). Once considered 
largely endemic to Western societies, T2DM has become an epidemic for many 
regional and cultural sectors worldwide. Amplifying the complications of the 
T2DM epidemic is the fact that these people are more likely to suffer from 
cardiovascular disease. Ultimately, as many as 90% of those with T2DM will 
suffer from cardiovascular disease in their lifetime (3).  
Other major health concerns such as hypertension, dyslipidemia and 
obesity are often associated with hyperglycemia or overt T2DM (4, 5). Clusters of 
these conditions have been termed metabolic syndrome (MetS), and patients 
with MetS and/or T2DM represent a population with a significantly elevated 
burden of cardiovascular disease (Figure 1-1), the leading cause of death in the 
United States and globally (3, 4, 6-10). It is estimated that the total direct and 
indirect cost of coronary heart disease and heart failure exceeded ∼140 billion 
dollars in the United States in 2010 (2).  
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Figure 1-1   Coronary heart disease and total cardiovascular disease 
mortality risk associated with MetS. The year-to-year % incidence of mortality 
is depicted for a group of 1209 Finnish men age 42-60 y that were initially without 
cardiovascular disease, diabetes or cancer. RR – relative risk; CI – confidence 
interval; y – years. Modified from Lakka HM et al, JAMA, 2002 (10).  
 
The disabling effects of heart disease are most evident during activity. Any 
increase in activity requires increased cardiac work to supply the body with 
oxygen rich blood and vital nutrition. Likewise, the increased demand on the 
heart must be matched with increased coronary blood flow. When the demands 
of cardiac work exceed perfusion the patient suffers cardiac ischemia, which 
often presents as angina pectoris. Thus, the relationship between coronary blood 
flow and metabolism (oxygen supply/demand) is being intensely investigated and 
therapies that act to rebalance this relationship are primary goals in the treatment 
and management of heart disease (11-52). Major ways in which this may be 
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accomplished are to increase coronary blood flow and shift cardiac metabolism 
to the utilization of more efficient substrate.       
Advancements in the treatment of MetS, T2DM, and heart disease singly 
and collectively are direly needed to reduce the individual and societal burdens. 
While reasons for increased adverse cardiac events and outcomes in the 
MetS/T2DM population are still active areas of investigation, impaired regulation 
of coronary vascular function and reduced cardiac glucose metabolism are 
believed to be important factors (11, 13, 14, 17-20, 22, 26, 27, 29, 33, 40, 43, 53-
56). Just as systemic glucose metabolism is impaired in this population, cardiac 
glucose metabolism is also impaired, and treatments that increase cardiac 
glucose uptake are being actively investigated (52-57).  Therefore, common 
underlying pathologies may explain these disease associations, and offer 
common targets for intervention. Furthermore, when developing new therapeutic 
interventions with cardiovascular implications it is important to determine the 
safety and efficacy in the MetS/T2DM population. 
Glucagon-like Peptide 1 and Systemic Glucose Regulation 
Recent advancements in the treatment of T2DM include drug therapies 
designed to utilize components of the incretin system specifically related to 
glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin hormone released from L-
cells of the small intestine in response to feeding as a 7-36 peptide, i.e. GLP-1 
(7-36). This peptide hormone is an agonist of the GLP-1 receptor (GLP-1R), a G-
protein coupled receptor. In pancreatic beta cells this ligand/receptor interaction 
increases PKA activity and insulin secretion in a glycemia-dependent manner 
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(58, 59). GLP-1 (7-36) is also known to increase insulin sensitivity and reduce 
glucagon secretion, which amplifies the glucose lowering effect (60-67). 
Importantly, the insulinotropic effects of GLP-1 (7-36) are dependent on 
hyperglycemia, thus pharmacologic stimulation of this incretin pathway typically 
does not result in frank hypoglycemia (Figure 1-2).    
Endogenously produced GLP-1 (7-36) has a very short plasma half-life of 
approximately 2 minutes (68, 69). It is cleaved by dipeptidyl-peptidase 4 (DPP-4) 
into GLP-1 (9-36), which is inactive as an insulinotropic/glucagonostatic agent 
and does not stimulate GLP-1R (70-74). A major advancement in the application 
of GLP-1 based therapies for systemic glucose control resulted from the 
discovery and subsequent research of a GLP-1R agonist, exendin-4. Exendin-4 
is a peptide initially found in saliva of the Gila monster (Heloderma suspectum), a 
venomous lizard endemic to deserts in the southwestern United States and 
northwestern Mexico (75, 76). In addition to being a potent GLP-1R agonist, 
exendin-4 is resistant to the actions of DPP-4, and has an extended plasma half-
life of ~25 minutes (Figure 1-2) (75, 77, 78).  
A synthetic version of exendin-4, exenatide, was developed with a goal of 
systemic glucose management in the setting of T2DM, and in 2005 exenatide 
was the first GLP-1 based drug to be approved by the Food and Drug 
Administration (FDA) (79). Current FDA approved drugs based on GLP-1 include 
GLP-1R agonists with extended plasma half-life’s (e.g. exenatide and liraglutide) 
and DPP-4 inhibitors (e.g. sitagliptin and vildagliptin) (80). Recent investigations 
suggest that therapies targeting GLP-1 pathways have beneficial pleotropic 
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effects including weight loss and improved lipid profiles, as well as more acute 
protective effect in the settings of stroke, heart failure and cardiac 
ischemia/reperfusion (62, 81-94). Therefore, additional investigations into the 
pleotropic effects of GLP-1 based therapies could be beneficial in not only further 
improving metabolic profiles in patients with MetS and/or T2DM, but also for 
acutely reducing morbidity and mortality in the settings of cardiac injury and 
failure. However, there is a paucity of information regarding the acute cardiac 
effects of GLP-1 in patients with MetS and/or T2DM.   
 
 
Figure 1-2   Depiction of the classical endocrine actions of GLP-1 (7-36) and 
the GLP-1R agonist Exendin-4 to regulate blood glucose. Notice that 
Exendin-4 is resistant to DPP-4 (Dipeptidyl peptidase-4), thus extending the 
plasma half-life.  
 
Although GLP-1 based therapies are most commonly prescribed in the 
setting of MetS/T2DM, there is some evidence for diminished responsiveness in 
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this group. In comparison to lean healthy controls there is a reduced, yet still 
effective, glucose stimulated insulinotropic effect of GLP-1 (7-36) in the setting of 
obesity/T2DM. Specifically, low dose intravenous infusion (0.5 pmol/kg/min) of 
GLP-1 (7-36) was demonstrated to increase glucose stimulated insulin secretion 
rate in obese/T2DM patients to match that of untreated healthy controls, however 
when the control group was given the same glucose/GLP-1 treatment there was 
a greater response (95). While this diminished effect on pancreatic beta cell 
function did not hinder the application of GLP-1 for the purpose of enhancing 
insulin secretion, the potential for clinically significant reductions in the acute 
cardiac effects of GLP-1 in this population remain largely unknown. Thus, such 
differential responsiveness to the cardiac effects of GLP-1 warrants further 
investigation. 
Glucagon-like Peptide 1 and the Heart 
Recently, the cardiac effects of GLP-1 have come into focus. Clinical 
investigations have revealed that intravenous (iv) GLP-1 increases cardiac 
performance in the settings of heart failure, coronary artery disease and 
ischemia/reperfusion injury (87, 90, 96, 97). For example, patients with chronic 
heart failure had significantly improved left ventricular ejection fraction (LVEF), 
VO2 max and 6 minute walk distance after receiving a 5 wk infusion of GLP-1 (7-
36) (2.5 pmol/kg/min iv) (87). Other investigations have demonstrated that 
shorter term infusions of GLP-1 (7-36) at concentrations of 1.2 to 1.5 pmol/kg/min 
can improve LVEF and regional contraction following ischemia/reperfusion in 
patients with congestive heart failure, increase left ventricular function during 
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dobutamine stress tests in patients with coronary artery disease while decreasing 
post-test myocardial stunning, and reduce the need for insulin and inotropic 
support following coronary artery bypass grafting (94, 96, 97).  
Information on the acute cardiac effects of GLP-1 in undamaged/healthy 
hearts is limited to a few studies in isolated rat and mouse hearts undergoing 
active coronary perfusion with physiologic buffer in a Langendorff preparation. In 
these studies, intracoronary administration of GLP-1 (7-36) increased coronary 
blood flow and myocardial glucose uptake in both rat and mouse heart (91, 93). 
However, while GLP-1 (7-36) increased left ventricular developed pressure 
(LVDP) in isolated mouse hearts, it decreased LVDP in isolated rat hearts. Under 
conditions of normal perfusion, GLP-1 (9-36) has only been tested in isolated 
mouse heart where it had no effect on LVDP or myocardial glucose uptake, but 
significantly increased coronary blood flow (93).  
More extensive studies have been undertaken to examine the cardiac 
effects of GLP-1 based therapies under the condition of ischemia/reperfusion. A 
small clinical study revealed that continuous iv infusion of GLP-1 (7-36) started at 
the time of reperfusion in patients with congestive heart failure resulted in a 
∼30% increase in left ventricular ejection fraction (LVEF) after 72 hours 
compared to saline control (90). While it is not clear if this effect resulted from 
decreased ischemic damage, it is consistent with a multitude of animal studies 
which have demonstrated that either iv and/or intracoronary GLP-1 (7-36), GLP-1 
(9-36), and GLP-1R agonists all reduce infarct size and increase left ventricular 
function following an ischemic event (91-93, 98-103). The DPP-4 inhibitor 
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sitagliptin has also been demonstrated reduce infarct size and increases left 
ventricular function in the setting of ischemia/reperfusion, as well as increase 
stroke volume in swine with heart failure (104-106).  
A recent investigation in swine determined that exenatide improves 
several measures of LV function and reduces infarct size when administered via 
combined iv/subcutanious (SQ) routes 5 minutes prior to release of a 75 minute 
complete left circumflex occlusion and continued via SQ administration for two 
days (Figure 1-3) (107). Consistent with this investigation in swine, a very recent 
clinical trial demonstrated the same magnitude of infarct size reduction when iv 
exenatide was administered just prior to and following reperfusion (108). 
However, the GLP-1R agonist liraglutide had a neutral effect on cardiac function 
and infarct size when administered SQ for three days preceding a 40 minute 
complete occlusion of the left anterior descending coronary artery (LAD) (109). In 
the liraglutide study, reperfusion only persisted for 2.5 hours. It is not clear if the 
differences in effect between exenatide and liraglutide in these studies are due to 
the route/timing of administration, duration of reperfusion, or perhaps differential 
cardiac actions of these two GLP-1R agonists.       
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Figure 1-3   Exenatide reduces myocardial infarct size in swine after a 75-
minute complete circumflex coronary artery occlusion. Myocardial infarct 
size as a percentage of the area at risk (AAR) (A). As a percentage of the total 
left ventricle (LV) (B). Phosphate-buffered saline (PBS) n = 9; exenatide n = 9. 
Representative images after Evans Blue and triphenyltetrazolium chloride 
staining are shown in C and D. Blue represents non-threatened myocardium, 
red indicates noninfarcted area within the area at risk, and white represents 
myocardial infarction. Figure taken from Timmers et al, 2009 (107).  
 
The increased cardiac performance observed in patients with heart failure 
receiving iv GLP-1 (7-36) is representative of what has been observed in canines 
with cardiac-pacing induced heart failure. Investigations in canines have 
demonstrated that intravenous GLP-1 (7-36) improves cardiac function and 
increase myocardial glucose uptake in the setting of heart failure. At doses of 1.5 
to 2.5 pmol/kg/min, intravenous GLP-1 (7-36) has been demonstrated to improve 
several parameters of cardiac function in canines with heart failure, such as 
LVEF, cardiac output and stroke volume (Figure 1-4) (88, 89, 94). Interestingly, 
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in this canine model of heart failure, GLP-1 (9-36) conveys nearly identical 
improvements in LV function, and increases in myocardial glucose uptake, as a 
dose/duration equivalent infusion of GLP-1 (7-36) (110). 
 
   
Figure 1-4   GLP-1 (7-36) significantly improves cardiac left ventricular 
function in canines with heart failure (n=16). Dose – 1.5 pmol/kg/min for 48 
hours; CHF – Congestive Heart Failure. Modified from Nikolaidis LA et at, 2004 
(89).  
 
Glucagon-like peptide 1: Mechanisms of Cardiac Action 
Myocardial expression of GLP-1R has previously been confirmed in 
canine heart, as well as the myocardium, coronary smooth muscle and coronary 
endothelium of mice (93, 94). Investigations using GLP-1R KO mice have been 
conducted to determine the role of GLP-1R in mediating the left ventricular 
performance enhancing effects of exendin-4, GLP-1 (7-36), and GLP-1 (9-36). 
The results of these investigations are inconsistent, and clear explanations are 
lacking. Exendin-4, GLP-1 (7-36), and GLP-1 (9-36) all increased cardiac 
performance following ischemia/reperfusion in isolated hearts from both wild type 
and GLP-1R KO mice (93, 102). Although GLP-1R dependent pathways may 
also contribute to the beneficial cardiac effects of exendin-4, these findings 
suggest that non-GLP-1R pathways mediated the direct cardiac actions in this 
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study. It was also determined that the use of a DPP-4 inhibitor abolished the 
cardiac actions of GLP-1 (7-36) in GLP-1R KO, but not wild type, mouse hearts 
(93). Thus indicating that in the absence of a cardiac GLP-1R, the direct cardiac 
actions of GLP-1 are mediated by GLP-1 (9-36), but that the effects of intact 
GLP-1 (7-36) are GLP-1R dependent. Such similar effects of GLP-1R agonists, 
GLP-1 (7-36) and GLP-1 (9-36) have also been observed in large animal models, 
as discussed above (107, 110). Taken together, these data indicate that exendin-
4 and GLP-1 (9-36) have cardioprotective value not related to the cardiac GLP-
1R, but that the direct cardiac actions of intact GLP-1 (7-36) are GLP-1R 
dependent. Importantly, GLP-1R agonists, GLP-1 (7-36), and GLP-1 (9-36) have 
all been demonstrated to convey beneficial cardiac effects. Furthermore, 
continued systemic administration of GLP-1 (7-36) also increases circulating 
GLP-1 (9-36) thus taking advantage of the cardioprotective potential of these two 
separate, yet related, peptides (72, 111).  
Potential physiological mechanisms for the actions of GLP-1 based 
therapies to increase left ventricular function and reduce infarct size include 1) 
inotropic effects 2) effects on substrate metabolism, and 3) effects on coronary 
blood flow. It is conceivable that the increases in cardiac function observed with 
treatments based on GLP-1 are due to inotropic actions, and not necessarily 
related to cardioprotection. However, there is evidence that inotropic and/or 
adrenergic stimulation are not responsible for increased cardiac performance in 
the setting of GLP-1 based therapy.  
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GLP-1 as an inotrope 
Classic cardiac inotropic/adrenergic stimulation is mediated in part by an 
increase in cAMP production and subsequent activation of PKA. While GLP-1R 
activation in pancreatic beta cells signals through this pathway, several 
investigations suggest that the cardiac actions of GLP-1 are not mediated by 
cAMP/PKA (91, 94), although not a point of complete agreement (93, 101). 
Furthermore, since these therapies are effective in isolated hearts and are not 
associated with increased heart rate it is not likely that sympathetic/adrenergic 
activation is involved (89, 91). Finally, previous studies have demonstrated a lag 
time of hours between the increases in glucose uptake and the cardiac 
performance-enhancing effects, which is distinctly different than classic 
sympathetic/adrenergic stimuli (94). The majority of evidence suggests that some 
combination of augmented myocardial glucose uptake, greater mechanical 
efficiency, increased coronary blood flow, and/or myocardial tissue preservation 
is responsible for the gains in left ventricular performance (89, 93, 102).   
GLP-1 and Myocardial Glucose Uptake 
Increasing myocardial glucose uptake has been a target for 
cardioprotection for decades (52, 57, 112-117). Some of the theory behind this 
approach is based on knowledge that glucose has a high P/O ratio (ATP 
produced per oxygen consumed), and that increased glucose metabolism can 
drive a reduction in fatty acid metabolism (i.e. Randle Cycle) (112, 118-120). At 
the level of mitochondrial oxidative metabolism, fatty acid has a lower P/O ratio, 
greater futile cycling, and generates more reactive oxygen species than does 
glucose metabolism (53, 118). Thus, increasing myocardial glucose uptake 
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should improve cardiac efficiency, allow maintenance of a high-energy state, 
protect cardiac tissue from oxidative damage and increase performance in 
underperfused tissue. This would be beneficial not only in terms of protecting the 
heart from ischemic injury, but also in terms of maintaining cardiac output to 
sustain tissue function and survival at an organismal level.  
Experimental data support the rationale behind targeting myocardial 
substrate metabolism for the purpose of disease intervention. Earlier studies from 
our lab have demonstrated that insulin increases cardiac function and efficiency 
in the setting of ischemia, effects also related to increased myocardial glucose 
uptake (52, 57). While this was an important finding, the clinical perspectives for 
using insulin to mitigate myocardial injury in an acute setting have been limited. 
Reasons for this limitation include problems associated with the acute use of 
intensive insulin therapy in patients with failing hearts, such as a significant risk 
of hypoglycemia and hypokalenmia, as well as the requirement for large volumes 
of iv glucose solution to maintain euglycemia (121-123). High iv fluid 
requirements result in higher volume loads on the heart (i.e. increased metabolic 
demand), likely offsetting the gains in metabolic efficiency acquired by increased 
myocardial glucose utilization. 
GLP-1 has been demonstrated to increase myocardial glucose uptake and 
cardiac efficiency (Figure 1-5), with significantly less risk and lower volume 
requirements than insulin (89).  Previous studies in isolated hearts from mice and 
rats indicate that intracoronary GLP-1 (7-36) increases myocardial glucose 
uptake under control conditions and following ischemia (91, 93). Other studies in 
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canines have determined that systemic administration of both GLP-1 (7-36) and 
GLP-1 (9-36) increase myocardial glucose uptake in the setting of pacing 
induced heart failure, an effect demonstrated to work both independently and 
synergistically with insulin (89, 110). 
 
 
 
 
                   
 
 
 
 
Figure 1-5   GLP-1 (7-36) significantly increases cardiac stroke work (A), 
mechanical efficiency (B), and glucose uptake (C) in canines with heart 
failure (n = 16). Dose – 1.5 pmol/kg/min for 48 hours; CHF – Congestive Heart 
Failure. Modified from Nikolaidis LA et at, 2004 (89).     
 
Both GLP-1 (7-36) and GLP-1 (9-36) have been demonstrated to increase 
left ventricular performance and myocardial glucose uptake (93, 102, 110). 
B 
C 
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Which suggest that the cardiac insulinomimetic effects are GLP-1R independent. 
There are recent data indicating that this effect is mediated by non-canonical 
GLP-1 signaling involving NO, p38-MAPK, and GLUT-1. Inhibition of p38-MAPK 
with SB203580 or inhibition of nitric-oxide synthase (NOS) with nitro-L-arginine 
(N-LA) was able to reduce the salutary effects of systemic GLP-1 (7-36) on 
myocardial glucose uptake in canines (94). Likewise, it has been demonstrated 
that GLP-1 (7-36) increases myocardial glucose uptake, p38-MAPK activity, nitric 
oxide production, and membrane GLUT-1 expression when administered via 
intracoronary infusion into isolated rat hearts or when administered intravenously 
in canines (91, 94).  
Acute increases in striated muscle (i.e. skeletal and cardiac) glucose 
uptake are classically attributed to membrane insertion of cytoplasmic GLUT-4 
vesicles (124-126). GLUT-1 is typically thought of as managing basal glucose 
uptake, not acute changes (126). However, cardiac GLUT-1 has become 
increasingly recognized for a role in mediating acute changes in glucose uptake 
(127, 128). GLP-1 (7-36) has been demonstrated to significantly increase 
myocardial glucose uptake in normally perfused isolated rat hearts within minutes 
of administration without effecting membrane GLUT-4, but increasing membrane 
GLUT-1 content (91). This acute time frame indicates that these effects are not 
mediated by transcriptional regulation, but rather membrane trafficking. In the 
post-ischemic rat heart GLP-1 (7-36) acutely increased membrane content of 
both GLUT-1 and GLUT-4 (91). Thus, current data indicate that GLP-1 augments 
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myocardial glucose uptake via mechanisms involving NO, p38-MAPK, and 
GLUT-1 with conditional effects on GLUT-4.  
GLP-1 stimulated increases in myocardial glucose uptake were associated 
with the same cellular signaling cascade when administered into the coronary 
circulation of isolated rat hearts, and administered intravenously in canines with 
heart failure. However, this insulinomimetic effect occurred within 30 minutes in 
isolated rat heart (91), while a longer infusion time of approximately 6 hours was 
required in canines (94). This difference is most likely due to the fact that a 
longer infusion time was used with systemic administration to reach plasma 
concentrations equal to that used for intracoronary infusion (∼400 to 500 pmol/L). 
The salutary effects on myocardial glucose uptake may be particularly 
relevant to patients with MetS and/or T2DM. These conditions are associated 
with a shift in myocardial substrate metabolism, which decreases the contribution 
of glucose to total cardiac energy supply while increasing fatty acid uptake (53-
56). Drug therapies based on GLP-1 may improve cardiac glucose metabolism in 
this patient population. In addition to enhancing the actions of insulin on 
myocardial glucose uptake, GLP-1 has been demonstrated to increase cardiac 
glucose uptake independently of insulin, and by mechanisms not associated with 
insulin mediated glucose uptake. This is promising since insulin resistance is 
common among these patients. However, the cardiometabolic effects of GLP-
1 have not been directly investigated in the settings of obesity/MetS or 
T2DM. While it is speculated that GLP-1 may be of particular benefit patients with 
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MetS/T2DM, it remains possible that the cardiac effects are impaired in this 
patient population. 
GLP-1 and Coronary Blood Flow 
There are several lines of evidence that GLP-1 may protect the heart from 
ischemic injury by augmenting coronary blood flow. Intracoronary GLP-1 (7-36) 
has been shown to increase coronary blood flow in isolated mouse and rat hearts 
(91, 93). Furthermore, intracoronary administration of both GLP-1 (7-36) and 
GLP-1 (9-36) have been demonstrated to increase coronary blood flow in 
isolated hearts from both wild type and GLP-1R KO mice under conditions of 
normal perfusion, and following ischemia (93). Other studies have demonstrated 
that GLP-1 (7-36) induces vasodilation in isolated aortic, femoral, and pulmonary 
arteries from rats (129-132).  
Systemic administration of GLP-1 (7-36) into canines was demonstrated to 
modestly increase coronary blood flow in one study; however, this increase in 
blood flow was also associated with an increase in MVO2. Thus it is unclear if the 
GLP-1 was acting as a coronary vasodilator, or if the increased coronary blood 
flow was a direct result of elevated metabolic demand (89). In other studies, 
neither iv GLP-1 (7-36) nor GLP-1 (9-36) increased coronary blood flow in 
canines (94, 110). There were also no increases in MVO2 in these other canine 
studies. Acute infusion of GLP-1 (7-36) (10 pM/kg/min IV) into swine immediately 
following cardiac fibrillation/resuscitation had no effect on coronary blood flow at 
1 or 4 hours, but did increase the flow response to intracoronary adenosine (an 
index of coronary flow reserve) at these time points (133).  
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Taken together, these data indicate that GLP-1 may have direct cardiac 
effects to increase coronary blood flow. However, the effects of intracoronary 
GLP-1 vs. that of iv GLP-1 have not been tested in the same animal species. 
Therefore, it is unknown if the differential responses are due to the route of 
administration and/or species differences. Furthermore, the effects of GLP-1 on 
coronary blood flow and vascular tone are unknown in humans and in the 
settings of MetS/T2DM. Further studies to determine the effects of GLP-1 on 
coronary blood flow and vascular tone are needed. 
Summary      
Patients with MetS and/or T2DM have an elevated risk for cardiovascular 
disease, the leading cause of mortality in the United States and globally (3, 4, 8-
10). While the reasons for increased adverse cardiac events and outcomes in the 
MetS and T2DM populations are still active areas of investigation, coronary 
microvascular dysfunction and reduced cardiac glucose metabolism are 
implicated in having key roles (14, 26, 42, 53-55). Thus, improving myocardial 
oxygen delivery and promoting more efficient cardiac substrate utilization; i.e. 
restoring the balance of myocardial oxygen supply and demand, are primary 
targets for advancing the treatment and management of obesity-related 
cardiovascular disease. 
Therapies based on GLP-1 are currently used for systemic glucose 
management in the setting of T2DM, and recently there has been interest in 
potential cardioprotective actions of GLP-1.  Multiple studies have revealed that 
GLP-1 based drugs increase left ventricular performance in the damaged/failing 
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hearts of humans, swine, canines, rabbits, rats and mice (Table 1-1). Increases 
in myocardial glucose uptake and/or coronary blood flow are associated with this 
cardiac performance-enhancing effect, and thought to play a critical role (Table 
1-1). These findings indicate that GLP-1 may be beneficial in treating the 
underlying pathology of obesity related heart disease. While the cellular 
mechanisms responsible for mediating the cardiac actions of GLP-1 are still 
under investigation, p38-MAPK and/or PKA dependent signaling pathways have 
been implicated (93, 94). 
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Specific Aims 
Despite an abundance of data indicating that intravenous infusion of GLP-
1 is cardioprotective (Table 1), information is lacking on the acute/sub-acute 
cardiac effects of GLP-1 in the MetS or T2DM population. It was recently 
recognized that the insulinotropic effect of GLP-1 is diminished, although still 
effective, in the setting of obesity/T2DM (95). However, whether obesity, MetS, 
and/or T2DM alter the cardiac actions of GLP-1 has not been directly evaluated. 
Thus, while GLP-1 may be useful in the treatment and management of obesity 
related heart disease by improving coronary microvascular function and 
myocardial glucose uptake, there is a distinct possibility that the cardiac actions 
of GLP-1 are impaired in the settings of obesity/MetS and T2DM. Some 
important questions remaining are 1) what are the direct, dose-dependent 
cardiac effects of GLP-1 in-vivo 2) are the cardiac effects influenced by cardiac 
demand (MVO2) and/or ischemia, 3) does GLP-1 effect myocardial blood flow, 
glucose uptake or total oxidative metabolism in human subjects, and 4) are the 
cardiac effects of GLP-1 treatment impaired in the settings of obesity/MetS and 
T2DM. 
Accordingly, the goal of the present application is to more fully elucidate 
the cardiac actions of GLP-1, determine if these actions are impaired in the 
setting of obesity/MetS, and uncover potential mechanisms of impairment. We 
hypothesize that GLP-1 will have direct cardiac actions which increase 
myocardial blood flow, glucose uptake, and function during ischemia. We also 
hypothesize that the milieu of obesity, MetS and T2DM may impair the cardiac 
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effects of GLP-1 by mechanisms involving GLP-1R expression, p38-MAPK 
signaling and/or PKA signaling. This hypothesis will be examined by translational 
studies in open-chest canines, our novel Ossabaw swine model of obesity/MetS, 
and humans with MetS/T2DM. We propose to accomplish our goal by pursuing 
the following Specific Aims: 
Aim 1: Determine the acute, dose-dependent cardiac effects of 
intracoronary GLP-1 under conditions of normal coronary perfusion and 
during ischemia. Approach: Open-chest anesthetized canines will be studied 
under conditions of normal coronary perfusion and during ischemia by measuring 
indices of cardiac function, as well as myocardial blood flow, glucose uptake, and 
total oxidative metabolism with and without acute intracoronary infusion of GLP-1 
(7-36) (10 pmol/L to 1 nmol/L). Myocardial biopsies will be obtained for 
determination of GLP-1 receptor localization.    
Aim 2: Test the hypothesis that obesity/MetS impairs the cardiac responses 
to GLP-1, and investigate potential mechanisms of such impairment. 
Approach: Parallel studies will be conducted in humans and swine. Human 
subjects with MetS/T2DM will be studied using a triple-tracer PET approach to 
measure myocardial blood flow, glucose uptake, fatty acid uptake, and total 
oxidative metabolism with and without GLP-1 (7-36) (1.5 pmol/kg/min iv). 
Measurements of cardiac function will be made using impedance cardiography. 
Control data will be available from identical studies in lean subjects participating 
in a separate investigation. Concurrently, chronically instrumented lean and MetS 
Ossabaw swine will be studied at rest and during graded treadmill exercise by 
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measuring hemodynamic variables, as well as myocardial blood flow, glucose 
uptake, and total oxidative metabolism with and without GLP-1 (7-36) (1.5 
pmol/kg/min iv). Myocardial biopsies will be obtained from lean and MetS swine 
to examine potential signaling pathways activated by GLP-1.  
 This project has direct clinical significance, and will demonstrate translation 
between mechanistic animal studies and effects observed in humans. These 
studies will be informative regarding mechanisms of, and novel treatment 
modalities for, MetS-induced cardiovascular disease.  
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Chapter 2 
 
Intracoronary glucagon-like peptide 1 preferentially augments glucose 
uptake in ischemic myocardium independent of changes in coronary flow 
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Abstract 
We examined the acute dose-dependent effects of intracoronary GLP-1 
(7-36) on coronary vascular tone, cardiac contractile function and metabolism in 
normal and ischemic myocardium. Experiments were conducted in open chest, 
anesthetized dogs at coronary perfusion pressures (CPP) of 100 and 40 mmHg 
before and during intracoronary GLP-1 (7-36) infusion (10 pmol/L to 1 nmol/L). 
Isometric tension studies were also conducted in isolated coronary arteries. 
Cardiac and coronary expression of GLP-1 receptors (GLP-1R) was assessed by 
Western Blot and immunohistochemical analysis.  GLP-1R was present in 
myocardium and the coronary vasculature.  Tension of intact and endothelium-
denuded coronary artery rings was unaffected by GLP-1. At normal perfusion 
pressure (100 mmHg), intracoronary GLP-1 (7-36) (targeting plasma 
concentration 10 pmol/L to 1 nmol/L) did not affect blood pressure, coronary 
blood flow, or myocardial oxygen consumption (MVO2); however, there were 
modest reductions in cardiac output and stroke volume. In untreated control 
hearts, reducing CPP to 40 mmHg produced marked reductions in coronary 
blood flow (0.50 ± 0.10 to 0.17 ± 0.03 ml/min/g; P < 0.001) and MVO2 (27 ± 2.3 to 
15 ± 2.7 µl O2/min/g; P < 0.001). At CPP = 40 mmHg, GLP-1 had no effect on 
coronary blood flow, MVO2, or regional shortening, but dose-dependently 
increased myocardial glucose uptake from 0.11 ± 0.02 µmol/min/g at baseline to 
0.17 ± 0.04 µmol/min/g at 1 nM GLP-1 (P < 0.001). These data indicate that 
acute, intracoronary administration of GLP-1 (7-36) preferentially augments 
glucose metabolism in ischemic myocardium, independent of effects on cardiac 
contractile function or coronary blood flow.  
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Keywords: coronary blood flow, myocardial oxygen consumption, GLP-1, canine, 
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 Introduction 
Glucagon-Like Peptide 1 (GLP-1) is an insulinotropic hormone released 
from intestinal L-cells in response to feeding.  The full-length peptide GLP-1 (7-
36) is a ligand for the G-protein coupled GLP-1 receptor (GLP-1R).  GLP-1 (7-36) 
is quickly degraded by circulating dipeptidyl peptidase 4 (DPP-4) to yield GLP-1 
(9-36), which does not activate the GLP-1R, and is inactive as an insulinotropic 
agent (134). Endogenous plasma concentrations of GLP-1 (7-36) observed in 
humans range from ~5 to 30 pmol/L in a fasting state to ~30 to 40 pmol/L 
following a mixed meal (135-138). Current GLP-1 based therapeutics for the 
treatment of type 2 diabetes mellitus include GLP-1R agonists with long 
circulating half-lives (e.g. exenatide), and DPP-4 inhibitors (e.g. sitagliptin) (139). 
Although these therapies have been linked with cardioprotective mechanisms, 
they are not currently prescribed for this purpose (53, 88-94, 100, 101, 110, 140). 
Recent research on the cardiac effects of GLP-1 indicates that systemic 
infusion of the full-length (7-36) peptide influences cardiac contractile function 
and glucose utilization. Studies in humans and in canines demonstrate that 
intravenous administration of GLP-1 (7-36) (1.5 to 2.5 pmol/kg/min) for 24 to 72 
hours improves cardiac contractile performance following coronary artery 
occlusion, (88, 90) and pacing-induced heart failure (89, 94, 110). This 
improvement in cardiac function is associated with an increase in myocardial 
glucose utilization and occurs both independently and synergistically with insulin 
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(89, 110). Other studies have documented that GLP-1 (7-36) induces vasodilation 
of isolated aortic, femoral, and pulmonary arteries in rats (129-132), and 
increases coronary blood flow in normal and post ischemic isolated murine 
hearts (91, 93). Systemic administration of recombinant GLP-1 (7-36) has also 
been shown to increase coronary blood flow in-vivo in canines with pacing 
induced dilated cardiomyopathy (89). However, cardiac contractile performance 
and myocardial oxygen consumption (MVO2) were also increased by GLP-1 in 
this study. Thus, it is unclear if the changes in coronary flow were the result of 
direct actions of GLP-1 on the coronary circulation or if they were the result of 
increased metabolic demand, i.e. metabolic vasodilation. While it has been 
demonstrated by Western Blot that GLP-1R is present within canine myocardium 
(94), the distribution of GLP-1R within canine heart, including the possible 
presence within coronary microvessels, has not previously been determined.  
Taken together, these findings suggest that GLP-1 (7-36) could protect the heart 
from ischemic injury by shifting cardiac substrate metabolism toward glucose 
and/or by augmenting myocardial perfusion (52, 53). Whether these effects of 
GLP-1 in-vivo occur acutely (minutes vs. hours) and/or are dependent on whole-
body responses to systemic exposure to GLP-1 has not been assessed.  
This study tested the hypothesis that acute administration of GLP-1 (7-36) 
directly into the coronary circulation augments coronary blood flow, myocardial 
glucose metabolism and cardiac contractile function in normal and ischemic 
myocardium in a dose-dependent manner. Experiments were conducted in open 
chest anesthetized dogs at coronary perfusion pressures (CPP) of 100 and 40 
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mmHg before and during intracoronary GLP-1 (7-36) infusion (intracoronary 
concentrations of 10 pmol/L to 1 nmol/L).  Coronary vascular effects of GLP-1 (7-
36) (10 pmol/L to 1 nmol/L) were also assessed by isometric tension studies in 
isolated coronary arteries. In addition, cardiac and coronary expression of GLP-
1R was determined by Western Blot analysis and immunohistochemistry with 
confocal microscopy. 
Methods 
Surgical preparation. Animal procedures used for this investigation were 
approved by the Institutional Animal Care and Use Committee and conducted in 
accordance with guidelines in the Guide for the Care and Use of Laboratory 
Animals. Adult male mongrel dogs weighing ~20 kg were sedated with morphine 
(3mg/kg, subcutaneous) and anesthetized with α-chloralose (100 mg/kg, 
intravenous). Following intubation, animals were ventilated with room air 
supplemented with oxygen, and positive end-expiratory pressure was held at ~2 
cm H2O to prevent atelectasis. Aortic pressure was measured through a catheter 
introduced into the thoracic aorta through the left femoral artery. Another 
catheter, inserted into the right femoral vein was used to maintain anesthesia, 
and administer sodium bicarbonate as needed to maintain pH within normal 
physiological limits. The right femoral artery was also catheterized to supply 
blood to a pump perfusing the left anterior descending coronary artery (LAD). A 
left lateral thoracotomy was then performed to expose the heart. The LAD was 
isolated distal to its first major diagonal branch, cannulated, and connected to the 
extracorporeal perfusion system. Coronary perfusion pressure was maintained 
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constant at 100 or 40 mmHg during the experimental protocol by a servo-
controlled roller pump. Coronary blood flow was measured within the 
extracorporeal perfusion circuit with an in-line flow transducer (Transonic 
Systems, Inc., Ithaca, NY, USA).  Intravenous heparin was administered (500 
U/kg) to prevent coagulation. The great cardiac vein was also cannulated to 
collect blood for metabolic analysis of the LAD perfusion territory. Left ventricular 
(LV) pressure and cardiac output (CO) were measured with a Millar® Mikro-Tip 
SPR-524 catheter in the LV (Millar Instruments, Inc., Houston, TX, USA), and a 
flow probe around the root of the aorta (Transonic Systems, Inc) respectively. 
Regional contractile function was determined using ultrasonic crystals 
(Sonometrics, Inc., London, ON, Canada) placed in myocardium of the LAD 
perfusion territory at a depth of ~7mm. These data were analyzed by custom-
made software developed in Matlab® (Mathworks®, Natick, MA, USA). Percent 
segment shortening was calculated as [(end diastolic length – end systolic 
length) / end diastolic length]. End diastolic length was taken at the beginning of 
the positive deflection of LV dP/dt (rate of pressure delevelopment), and end 
systolic length was taken 20 ms before the peak negative deflection of dP/dt, 
corresponding with the dicrotic notch of the aortic pressure recording, as 
previously reported (52, 141). All materials which were implanted into the animals 
or in contact with the circulation (i.e. cannulas, catheters and flow probes) were 
cleaned with the multi-enzyme detergent EnzyteTM (Decon Labs, Inc., King of 
Prussia, PA, USA) for the removal of blood, proteins, and other biological 
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material, then rinsed thoroughly with deionized water and allowed to dry prior to 
use.  
Acute dose-dependent effects GLP-1 (7-36) on cardiovascular 
hemodynamics. Acute in-vivo experiments were conducted in open chest, 
anesthetized dogs (n = 9) at CPP of 100 and then 40 mmHg before and during 
intracoronary GLP-1 (7-36) infusion (10 pmol/L to 1 nmol/L). Following 
cannulation of the LAD, hemodynamic and contractile function parameters were 
allowed to stabilize for ~10-15 min before acquiring baseline data. After baseline 
parameters were measured and blood samples obtained, an infusion of GLP-1 
(7-36) (G8147; Sigma Aldrich, St. Louis, MO, USA) was initiated into the LAD 
perfusion line at a constant infusion rate in order to obtain coronary plasma 
concentrations of 10 pmol/L to 1 nmol/L. Plasma flow was calculated as [(1-
hematocrit) X coronary blood flow]. After completion of the GLP-1 (7-36) infusion 
at CPP = 100 mmHg, a 10 minute washout period was allowed before CPP was 
lowered to 40 mmHg. Following stabilization of hemodynamic parameters at CPP 
= 40 mmHg (~5 to 10 min), baseline data were acquired and the intracoronary 
infusion of GLP-1 (7-36) repeated. Data were averaged from 10 consecutive 
beats following ∼5 min of GLP-1 (7-36) administration at each dose.  
Metabolic Analysis. Arterial and coronary venous blood were collected 
simultaneously, immediately sealed, and placed on ice.  The samples were 
analyzed for pH, PCO2, PO2, O2 content, hematocrit, glucose concentration, and 
lactate concentration with an Instrumentation Laboratories automatic blood gas 
analyzer (GEM Premier 3000; Instrumentation Laboratory Company, Bedford, 
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MA, USA) and CO-oximeter (682) system (Instrumentation Laboratory 
Company). LAD perfusion territory was estimated to be 30% of total heart weight, 
as previously described by Feigl et al. (141) MVO2 (µl O2/min/g) was calculated 
as [coronary blood flow X (arterial O2 content – coronary venous O2 content)]. 
Fick principle was also used to calculate glucose and lactate uptake.  
Functional assessment of isolated coronary artery rings. Isometric tension 
studies were conducted in both endothelium intact and denuded isolated 
coronary artery rings treated with the same concentrations of GLP-1 used in the 
in-vivo studies (10 pmol/L to 1 nmol/L). For these experiments canine hearts 
were excised, immediately rinsed, and bathed with ice-cold saline. Epicardial LV 
coronary arteries were dissected from the heart, cleaned of perivascular fat, and 
cut into ~3 mm rings. These fresh arterial rings were mounted in organ baths with 
warm oxygenated Krebs solution and brought to an optimal preload of ~4 g, as 
previously described (142). Rings were then pre-constricted with the 
thromboxane A2 mimetic U46619 (1 µmol/L). Graded doses of GLP-1 (7-36) were 
then added to the baths in a cumulative manner.  Presence or absence of 
functional endothelium was assessed by reactivity to acetylcholine (10 µmol/L). 
Viability of arterial smooth muscle was determined by reactivity to sodium 
nitroprusside (20 µmol/L). 
Western blot analysis. Following excision of the hearts, transmural LV 
samples were quickly isolated, snap frozen in liquid N2, and stored at -80˚C. 
These samples were later homogenized in lysis buffer, and protein was 
quantitated using a DC protein assay.  35 µg of protein was loaded onto a 7.5% 
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acrylamide gel and transferred overnight.  Membranes were blocked prior to a 1 
hour incubation with rabbit polyclonal GLP-1R antibody (ab39072; Abcam, 
Cambridge, MA, USA) in blocking buffer with 0.1% Tween 20 at ambient 
temperature.  Membranes were washed and incubated for 1 hour with IRDye 800 
donkey anti-rabbit secondary antibody. Immunoreactivity to GLP-1R was 
determined by a Li-Cor Odyssey system (Li-Cor Biosciences, Lincoln, NE, USA). 
Band size was determined using comparison with a standard protein ladder (161-
0375; BIO Rad, Hercules, CA, USA).  
Immunohistochemistry and confocal microscopy. Fresh LV cardiac 
samples were snap frozen in liquid N2 and stored at -80˚C. Frozen LV samples 
were then embedded in Tissue-Tek OCTTM (Sakura Finetek USA, inc, 
Torrance, CA, USA) and sliced into 10 µm sections.  Slices were incubated in 
mouse monoclonal antibodies against cardiac troponin I (ab10231; 1:1,000), 4’,6-
diamidino-2-phenylindole (DAPI; 100 ng/ml), and rabbit polyclonal antibodies 
raised against GLP-1R (ab39072; 1:25) for one hour. Slices were subsequently 
washed, and treated with anti-rabbit IgG and anti-mouse IgG secondary 
antibodies for 30 min, conjugated with alexa-488 and alexa-594, respectively. 
Slides were imaged using an Olympus2 single photon confocal microscope 
(Olympus America Inc., Center Valley, PA, USA).  
Statistical Analyses. Data are presented as mean ± SE.  Statistical 
comparisons were made with one-way repeated measures analysis of variance 
(ANOVA).  For all comparisons, P < 0.05 was considered statistically significant.  
When significance was found with ANOVA, a Student-Newman-Keuls multiple 
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comparison test was performed to identify differences between treatment levels 
and/or CPP. 
Results 
Cardiac and coronary expression of GLP-1R.  Western Blot analysis 
demonstrated staining of the GLP-1R in canine cardiac tissue with the predicted 
band at ~53 kilodaltons (kDa) (Figure 2-1 A).  Immunohistochemistry with 
fluorescence confocal microscopy confirmed GLP-1R expression (green) in the 
canine coronary vasculature and myocardium (Figure 2-1 B and 2-1 C).  Cardiac 
sections were counterstained with the nuclear stain DAPI (blue) and myocardial 
troponin I (red) to demonstrate cellular architecture in context to localization of 
GLP-1R. 
 
Figure 2-1   Cardiac and coronary expression of GLP-1R. High antibody 
selectivity for GLP-1R is demonstrated by Western Blot analysis (A). 
Fluorescence confocal microscopy demonstrated GLP-1R expression (green) in 
both myocardium and coronary vessels (B). Counter-staining of cardiac troponin 
I (red) and Nuclei (blue) identifies myocardial tissue and cellular architecture (C).  
 
Coronary vascular effects of GLP-1 (7-36). GLP-1 (10 pmol/L to 1 nmol/L) 
had no effect on isometric tension of isolated, endothelium intact and denuded 
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epicardial coronary rings (n = 5) pre-constricted with 1 µmol/L U46619 (Figure 2-
2 A). Endothelial denudation was confirmed by a lack of relaxation to 
acetylcholine (10 µmol/L) and smooth muscle viability confirmed by relaxation to 
sodium nitroprusside (20 µmol/L). GLP-1 also had no effect on basal tension of 
non pre-constricted coronary arteries (data not shown). Likewise, acute 
intracoronary administration of GLP-1 (7-36) (10 pmol/L to 1 nmol/L) had no 
effect on coronary blood flow (Figure 2-2 B) or coronary venous PO2 (Figure 2-2 
C) at either CPP = 100 mmHg or 40 mmHg (n = 9). 
 
Figure 2-2   Direct coronary vascular effects of GLP-1 (7-36). GLP-1 (7-36) 
had no effect on isometric tension of intact or endothelial denuded canine 
coronary artery rings preconstricted with U46619 (1 µM). Denudation was 
confirmed by a lack of responsive to Acetylcholine (Ach; 10 µM), and viability 
confirmed by relaxation to sodium nitroprussside (SNP; 20 µM) (A). Intracoronary 
infusion of GLP-1 (7-36), 10 pmol/L to 1nmol/L, had no effect on coronary blood 
flow (B) or coronary venous PO2 (C) at CPP=100 mmHg or 40 mmHg.    
 
Effects of GLP-1 (7-36) on global and regional indices of cardiac function. 
Hemodynamic data on the effects of GLP-1 in normal and ischemic hearts are 
provided in Table 2-1. A representative tracing of key hemodynamic data before 
and during GLP-1 (1 nmol/L) administration at CPP = 100 and 40 mmHg is 
shown in Figure 2-3. In these experiments we used a servo-controlled roller 
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pump system to maintain perfusion pressure constant at 100 mmHg and 40 
mmHg. This servo-controlled system maintains pressure at these set values by 
alternating the frequency of a roller pump. Therefore, the phasic nature observed 
in coronary flow is not reflective of the cardiac cycle but due to the disruption of 
flow by the pump rollers (Figure 2-33). Acute intracoronary administration of 
GLP-1 dose-dependently decreased stroke volume and cardiac output at CPP = 
100 mmHg. Although heart rate tended to be higher (P = 0.07), mean arterial 
pressure and the maximal rate of LV pressure development and relaxation 
(+dP/dt max and –dP/dt min) were unaffected by GLP-1. Reduction of CPP to 40 
mmHg decreased stroke volume and cardiac output (P < 0.05) but did not alter 
blood pressure or heart rate relative to untreated control conditions at CPP = 100 
mmHg. GLP-1 had no effect on blood pressure, heart rate or indices of global 
cardiac function at CPP = 40 mmHg. Indices of regional cardiac contractile 
function in the LAD perfusion territory were also unaffected by intracoronary 
administration of GLP-1 (7-36) at either CPP = 100 or 40 mmHg (Figure 2-4). 
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Figure 2-3   Example of original recordings of aortic pressure (AoP), left 
ventricular pressure (LVP), cardiac output (CO), coronary blood flow (Cor Flow), 
and segment length with and without intracoronary GLP-1 (7-36) (1 nmo/L) at 
coronary perfusion pressures (CPP) of 100 and 40 mmHg from a single canine. 
 
	  
	  
38	  
 
Figure 2-4   Direct effects of GLP-1 (7-36) on indices of regional cardiac 
function. Intracoronary infusion of GLP-1 (10 pmol/L to1 nmol/L) had no effect 
on the rate (A) or degree (B) of regional myocardial shortening at CPP = 100 
mmHg or 40 mmHg. 
 
Effects of GLP-1 (7-36) on myocardial substrate metabolism.  At CPP = 
100 mmHg, intracoronary administration of GLP-1 (7-36) (10 pmol/L to 1 nmol/L) 
had no effect on MVO2, myocardial lactate uptake, glucose uptake, or glucose 
extraction (Figure 2-5). In untreated hearts, reducing CPP to 40 mmHg resulted 
in the expected decrease in MVO2 (Figure 2-5A) and myocardial lactate uptake 
(Figure 2-5B).  Administration of GLP-1 (7-36) dose-dependently augmented 
glucose uptake at CPP = 40 mmHg (Figure 2-5C), increasing consumption by 
∼55% from baseline (0.11 ± 0.02 µmol/min/g) to the highest 1 nmol/L dose of 
GLP-1 (0.17 ± 0.04 µmol/min/g). Myocardial glucose extraction was also 
increased ∼85% at the highest dose of GLP-1 at CPP = 40 mmHg (Figure 2-5D). 
These changes in myocardial substrate metabolism induced by GLP-1 at CPP = 
40 mmHg did not significantly alter MVO2 relative to untreated baseline 
conditions (Figure 2-5A). 
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Figure 2-5   Direct dose-dependent effects of GLP-1 (7-36) on myocardial 
metabolism. GLP-1 did not effect myocardial oxygen consumption (A), or lactate 
uptake (B) at CPP=100 mmHg or 40 mmHg. GLP-1 (7-36) dose dependently 
increased myocardial glucose uptake (C) and extraction (D) at CPP=40 mmHg, 
but had no effect at CPP=100 mmHg. * P < 0.05 vs. baseline at the same CPP. 
 
Discussion 
 The purpose of this investigation was to evaluate the direct coronary and 
cardiac effects of GLP-1 (7-36) administration in-vivo. We tested the hypothesis 
that acute, intracoronary administration of GLP-1 (7-36) augments coronary 
blood flow, myocardial glucose metabolism and cardiac contractile function in 
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normal and/or ischemic hearts in a dose-dependent manner. The rationale was 
based on earlier studies indicating that systemic infusions of GLP-1 result in 
increased LV contractile function and myocardial glucose metabolism at baseline 
(93), and in conditions of cardiac stress (i.e. coronary artery occlusion (88, 90), 
pacing induced heart failure (94, 110). In addition, GLP-1 has also been shown to 
induce endothelium-dependent vasodilation of isolated systemic arteries (131), 
and to increase coronary blood flow in-vitro (91, 93), and in-vivo (89). However, 
whether these effects of GLP-1 are mediated by direct actions on the heart and 
coronary circulation independent of changes in MVO2, and/or by other indirect 
peripheral/central effects has not been established. Novel findings of the current 
study were that acute, intracoronary administration of GLP-1 (7-36): 1) did not 
directly affect coronary blood flow in-vivo or vascular tone in-vitro; 2) modestly 
reduced stroke volume and cardiac output at CPP = 100 mmHg without affecting 
arterial pressure; 3) did not influence MVO2, global or regional contractile 
function, or cardiac lactate uptake at CPP = 100 or 40 mmHg; 4) significantly 
increased myocardial glucose uptake and extraction, but only at CPP = 40 
mmHg. We also confirmed GLP-1R expression in the coronary vasculature and 
myocardium of canines. Taken together, these findings indicate that acute (~5 to 
10 min), intracoronary administration of GLP-1 (7-36) preferentially augments 
glucose metabolism in ischemic myocardium, independent of effects on cardiac 
contractile function or coronary blood flow.  
Coronary and cardiac expression of GLP-1R. Data from the present 
investigation confirm expression of GLP-1R in both the coronary vasculature and 
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myocardium. While previous studies have demonstrated expression of GLP-1R 
in canine myocardium (94), mouse heart and coronary vasculature (93), and 
isolated human coronary artery endothelial cells (143), we are the first group to 
demonstrate relative GLP-1R expression in canine coronary vasculature and 
myocardium. We observed GLP-1R expression in all layers of coronary arterial 
wall, including the endothelium and adventitia. Our results indicate GLP-1R has 
more uniform and ubiquitous expression in canine myocardium and coronary 
circulation (Figure 2-1B) than was previously shown in mice. Importantly, 
selective binding of the GLP-1R antibody used in this investigation at the 
specified protein band (53 kDa) was confirmed using Western Blot (Figure 2-
1A).  
Coronary vascular effects of GLP-1 (7-36). Our findings demonstrate that 
although GLP-1R is expressed in the coronary vasculature (Figure 2-1B), acute 
administration of GLP-1 does not directly modulate coronary vascular tone in-
vitro (Figure 2-2A) or in-vivo (Figure 2-2B). These data are in contrast with 
earlier studies which documented that GLP-1 induces endothelium-dependent 
vasodilation in isolated arteries, increases coronary blood flow in isolated hearts 
under normal conditions and during reperfusion, and following pacing induced 
cardiomyopathy in canines. However, such previous studies were conducted in 
aorta (130, 132), femoral (129), and pulmonary vessels (131), isolated rodent 
hearts (91, 93), and with systemic administration of recombinant GLP-1 (7-36) in 
canines.  It is also important to recognize that the increased coronary blood flow 
previously documented in-vivo in canines was accompanied by increases in 
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cardiac contractile function and MVO2 (89), the primary determinants of coronary 
flow (38). Thus, the effects of GLP-1 on coronary blood flow in those 
experimental conditions could have been mediated by direct effects on the 
vasculature and/or by indirect effects via metabolic vasodilation secondary to 
increased MVO2. The reasons for the discrepant findings regarding the vascular 
effects of GLP-1 are unclear but are likely related to differences in specific 
vessels studied, species investigated and/or dose and route of GLP-1 
administration. Regardless, our findings provide strong evidence that acute 
administration of physiologic/pharmacologic concentrations of GLP-1 directly in 
to the coronary circulation does not influence coronary vasomotor tone.  
Cardiometabolic effects of GLP-1 (7-36). Earlier studies indicate that GLP-
1 augments myocardial glucose metabolism under normal and post-ischemic 
conditions in isolated hearts (91, 93), and following cardiac ischemia and/or 
dilated cardiomyopathy in-vivo (89, 94, 110). However, we found that 
intracoronary administration of GLP-1 (7-36) preferentially and dose-dependently 
augments myocardial glucose metabolism during ischemia (CPP = 40 mmHg), 
but not during normal perfusion (CPP = 100 mmHg) (Figure 2-5). This finding is 
consistent with previous data indicating that GLP-1 augments myocardial glucose 
uptake under conditions of cardiac stress (e.g. ischemia/reperfusion injury, 
dilated cardiomyopathy) (89, 94, 110). Data from the current investigation extend 
this finding and demonstrate that acutely increasing coronary plasma GLP-1 
concentration to ~1 nmol/L increases glucose uptake of ischemic myocardium by 
~55%. Importantly, this effect was concentration dependent and differed from 
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other studies, which found that direct coronary administration of GLP-1 increases 
glucose uptake under normal conditions in isolated hearts (91, 93). Our results 
indicate that longer, systemic administration of GLP-1 is not mandatory for the 
insulinomimetic effect to be manifest and argue against peripheral/central actions 
of GLP-1 driving alterations in substrate metabolism. Whether the effect of GLP-1 
(7-36) on ischemic myocardial glucose metabolism is dependent on GLP-1R 
activation and/or actions of the (9-36) degradation product merits further 
investigation.  
Effects of GLP-1 (7-36) on regional and global indices of cardiac function. 
Several previous investigations have reported that GLP-1 increases indices of LV 
function (i.e. developed pressure, wall thickening, dP/dt and ejection fraction) 
during reperfusion, heart failure and dilated cardiomyopathy (88-90, 93, 94, 110). 
However, we observed no direct effect of acute intracoronary GLP-1 (7-36) 
infusion on indices of regional (Figure 2-4) or global cardiac contractile function 
during ischemia (Table 2). This finding is in contrast to our hypothesis that 
increases in glucose metabolism would improve contractile function in ischemic 
myocardium, as glucose has a high P/O ratio (ATP produced per oxygen 
consumed) and earlier data support that increased myocardial glucose 
metabolism improves cardiac efficiency during ischemia (52, 53, 112, 118-120). 
In particular, previous studies from our group documented that insulin-mediated 
increases in myocardial glucose metabolism significantly improve regional 
cardiac function in ischemic canine hearts (CPP = 40 mmHg) (52, 57). However, 
the increase in myocardial glucose uptake induced by insulin in these studies 
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(~0.50 µmol/min/g) was substantially higher than that reported in the present 
study (~0.20 µmol/min/g).  
Interestingly, we did observe a moderate dose-dependent decrease in 
stroke volume and cardiac output at normal perfusion pressure (CPP = 100 
mmHg), without corresponding changes in dP/dt or aortic pressure (Table 2). 
This reduction in cardiac output was associated with an ~10 beats/min increase 
in heart rate. Although there were no changes in dP/dt in our experiments, the 
reductions in stroke volume and cardiac output suggest GLP-1 reduced 
contractile performance. This observation is supported by a previous study in 
which recombinant GLP-1 (7-36) decreased LV developed pressure and dP/dt 
when infused into the coronary circulation of isolated rat hearts (91). Taken 
together, these findings indicate that direct (intracoronary) cardiac effects of 
GLP-1 differ from indirect (peripheral/central) effects.  
Limitations of the study. It is possible that that the assessment of regional 
myocardial substrate uptake and contractile function can be influenced by 
contamination of interventricular venous drainage by blood from non-LAD 
perfused myocardium and/or by collateral flow to the hypoperfused LAD 
perfusion territory. Importantly, an earlier study by Vinten-Johansen et al. 
conducted using systemically administered radioactively-labeled red blood cells 
demonstrated that blood taken from the anterior interventricular vein is almost 
exclusively from LAD perfused myocardium, even at CPP = 40 mmHg (144). Our 
laboratory also previously demonstrated that collateral flow to the LAD at a CPP 
of 40 mmHg is negligible (~0.01 ± 0.01 ml/min/g) (57). This finding is supported 
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by marked reduction of cardiac performance observed when CPP was lowered to 
40 mmHg (Table 2-1). Thus, our measurements of myocardial substrate 
metabolism computed from arteriovenous differences and LAD flow were likely 
not significantly affected by collateral flow or venous contamination. Further, any 
contamination of venous drainage would have resulted in dilution of the 
measures, and actually served to diminish our overall treatment effect on cardiac 
metabolism. Therefore, if such effects were present, the ~55% increase in 
glucose uptake would be an underestimate of the effect of GLP-1 in ischemic 
myocardium (Fig 2-5C).  While our studies examined the acute effects of 
intracoronary GLP-1 (7-36) on myocardial glucose, lactate and oxygen uptake, 
additional studies to also examine the effects of GLP-1 on the fates of other 
substrates such as fatty acids, triglycerides and myocardial glycogen stores are 
needed.  
GLP-1 infusions in this investigation were conducted after hemodynamic 
variables had stabilized at CPPs of 100 and 40 mmHg. Although it is possible 
that hemodynamic status could have changed over time, the relatively constant 
measures of coronary blood flow, cardiac function and MVO2 at each of these 
pressures argues for stability of the experimental preparation over time.  
Our observed regional segment shortening data were lower than what is 
typically reported in the literature (141, 145). These low values are likely related 
to differences in depth of crystal placement and/or local cardiac fiber orientation 
at the depth in which the crystals were placed. These aspects of crystal 
implantation environment are not controlled under the present experimental 
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protocol. It is also possible that the low observed values for regional segment 
shortening are due to myocardial stunning subsequent to cannulation of the LAD. 
However, we carefully monitor all hemodynamic variables before and following 
cannulation to ensure that these parameters return to baseline values prior to 
beginning the experimental protocol. These variables typically return to normal 
within ~2 min of reperfusion and we allowed at least a 10 minute recovery period 
to ensure adequate recovery time. Regardless of the signal magnitude, we did 
observe expected reductions in regional function during ischemia, and 
importantly GLP-1 did not affect segment shortening at normal coronary 
perfusion pressure (CPP = 100 mmHg) or during ischemia (CPP = 40 mmHg).   
Conclusion 
 Data from this investigation indicate that acute, intracoronary infusion of 
GLP-1 (7-36) preferentially augments glucose metabolism in ischemic 
myocardium, independent of effects on coronary blood flow. These findings 
demonstrate that the salutary effects of GLP-1 on myocardial glucose 
metabolism occur dose-dependently within minutes of intracoronary 
administration during ischemia. Thus acute cardiac administration of GLP-1 may 
be useful in modulating cardiac metabolism acutely in a setting where ischemia is 
anticipated, such as elective cardiac surgery. Our data also indicate that although 
GLP-1R is expressed in myocardium and coronary circulation, GLP-1 (7-36) 
does not affect coronary vasomotor tone or coronary flow when administered 
directly into canine coronary vasculature over an ~20 min time period. Further 
investigations to uncover direct and systemic mechanisms by which GLP-1 
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based treatments affect cardiac function and metabolism will be useful for 
determining the best strategies to optimize therapeutic utilization of these 
compounds.   
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Abstract 
This study examined the hemodynamic and cardiometabolic effects of 
intravenous glucagon-like peptide 1 (7-36) (GLP-1; 1.5 pmol/kg/min) in lean and 
metabolic syndrome (MetS) swine, and in lean and MetS/Type 2 Diabetic (T2D) 
humans. Under fasting conditions, GLP-1 did not affect blood pressure, heart 
rate, or coronary blood flow in humans or swine. In lean humans, GLP-1 
increased MGU over 4-fold (P = 0.03) and increased MVO2 by ~20% (P = 0.03). 
However, these effects were absent in obese humans with Type 2 diabetes 
mellitus. In lean exercising swine, GLP-1 augmented the myocardial glucose 
uptake (MGU) response to increasing MVO2 (P = 0.01). These effects of GLP-1 
were absent in MetS swine. Western blotting and immunohistochemistry 
demonstrated no differences in GLP-1 receptor content between lean and MetS 
swine in coronary (P = 0.95) or cardiac (P = 0.46) tissue. In myocardial tissue 
slices exposed ex-vivo, GLP-1 (1 to 5 nmol/L) dose dependently increased p38-
MAPK activity in lean (P =0.04) but this effect was absent in MetS swine. GLP-1 
did not affect myocardial PKA activity in either group. These data indicate that 
cardiometabolic responses to GLP-1 (7-36) are impaired in the setting of MetS 
and T2DM via diminished activation of p38-MAPK, without alterations in GLP-1 
receptor expression or PKA-dependent signaling. 
Introduction 
The increasing prevalence of Type 2 Diabetes Mellitus (T2DM) is a major 
health concern in the United States and globally (2, 9). Once considered largely 
endemic to Western societies, T2DM has become an epidemic for many regional 
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and cultural sectors worldwide (1). Other major health concerns such as obesity, 
hypertension, and dyslipidemia are often associated with hyperglycemia or overt 
T2DM (5, 146). Clusters of these risk factors are collectively described as the 
metabolic syndrome (MetS) (7, 147, 148). Patients with MetS and/or T2DM carry 
a significantly increased burden of cardiovascular disease (3, 10, 149). 
Approaches to restore the balance between myocardial oxygen delivery and 
metabolism during ischemia, i.e. improving myocardial oxygen supply and 
promoting more efficient cardiac substrate utilization, are currently being 
investigated as a means to improve the treatment and management of obesity-
related cardiovascular disease (14, 20, 26, 53, 150-152). 
Advancements in the treatment of T2DM include drug therapies designed 
to augment actions of the incretin system, in particular the actions of glucagon-
like peptide 1 (GLP-1) (153-174). GLP-1 is released from L-cells of the small 
intestine in response to feeding and is an agonist of the G protein-coupled 
receptor (GLP-1R) (134, 175). In pancreatic beta cells, this ligand/receptor 
interaction causes glucose-dependent increases in cyclic adenine 
monophosphase (cAMP) and phosphokinase A (PKA) activity, leading to 
increased glucose-stimulated insulin secretion (58, 59). GLP-1 based therapies 
are currently prescribed for systemic glucose management, and have recently 
come under investigation for potential cardioprotective actions (176-179). Several 
studies have revealed that intravenous administration of GLP-1 significantly 
reduces myocardial infarct size following ischemia/reperfusion injury and 
improves cardiac contractile function in the settings of coronary artery disease, 
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hear failure, and following myocardial ischemia (87-90, 94, 98, 110, 180, 181). 
While the mechanisms responsible for these effects of GLP-1 are not yet fully 
understood, increases in myocardial glucose uptake and coronary blood flow via 
a p38 mitogen-activated protein kinase (MAPK) and/or PKA dependent signaling 
pathway have been implicated (91, 93, 94, 101, 182). Although recent evidence 
suggests that the insulinotropic effects of GLP-1 are attenuated in the setting of 
MetS and T2DM (95, 183), data on the cardiovascular effects of GLP-1 in MetS 
or T2DM are critically lacking.  
 The goal of the present investigation was to examine whether MetS or 
T2DM influence the cardiovascular effects of GLP-1. To accomplish this goal, we 
performed studies in lean vs. MetS/T2DM humans and in lean vs. obese/MetS 
Ossabaw swine to examine the hypothesis that the myocardial actions (substrate 
metabolism and perfusion) of GLP-1 are impaired in the settings of MetS/T2DM. 
We further evaluated whether differences arose due to alterations in GLP-1 
receptor expression and/or downstream signaling through cAMP/PKA or p38-
MAPK pathways. Data from these studies provide the first evidence of defects in 
the functional metabolic effects of GLP-1 in-vivo and in-vitro in obesity/MetS and 
T2DM. 
Methods 
The human studies and protocols performed were approved by the 
Indiana University Institutional Review Board and conducted in accordance with 
the Declaration of Helsinki. Human subjects provided written informed consent 
for these investigations. The procedures and protocols performed in swine were 
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approved by the Indiana University Institutional Animal Care and Use Committee 
in accordance with the Guide for the Care and Use of Laboratory Animals. 
Human subjects inclusion criteria. All human subjects were between the 
ages of 18 and 50 years. Lean subjects were defined as having a BMI < 25 
kg/m2, in good general health, and taking no regular medications. Diabetic 
subjects were selected on the following basis: obese (BMI > 30 kg/m2 but < 40 
kg/m2), HbA1c 7.0 to 10.0%, and treated with diet and exercise plus oral agents 
or injected insulin.  
Human subjects exclusion criteria. Human subjects were excluded based 
on the following criteria: chronic illness (other than T2DM) or infection, known 
coronary artery disease or abnormal ECG on screening evaluation, blood 
pressure > 160/100 mmHg on two occasions during screening evaluations, total 
cholesterol > 240 mg/dL, treatment with GLP-1 agonist or DPP4 inhibitor within 6 
months, known intolerance to injected GLP-1 agonist, treatment with PPAR-γ 
agonist within 6 months, recognized microvascular complications (retinopathy, 
nephropathy, neuropathy), unwillingness or inability to use injected insulin, 
inability to remain supine and comfortable for the duration of the PET protocol, 
known or planned radiation exposure that would result in greater than 500 mrem 
total exposure in a contiguous 12 month period, and/or current pregnancy. 
Preparation of human subjects with T2DM. All human subjects with T2DM 
were placed on a uniform medication regimen for glucose management 
consisting of only glargine (Sanofi Aventis, Bridgewater, NJ, USA) and lispro (Eli 
Lilly and Company, Indianapolis, IN, USA) insulins two weeks prior to the 
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scheduled PET study. The night prior to PET studies blood samples were 
collected (minimum of 4 hours from the most recent meal) and hemodynamic 
parameters were measured, then subjects used their current meal bolus and 
nighttime basal insulin dosing to provide basal control of fasting sugar until 
completion of the PET protocol the following morning. In one subject, an 
overnight infusion of regular insulin (Eli Lilly and Company, Indianapolis, IN, 
USA) was used to achieve adequate fasting glucose overnight; this was 
discontinued for the subsequent PET scanning procedure, using only insulin 
glargine for ongoing glucose control. 
Human subjects study protocol. All studies were conducted with subjects 
in the fasting resting state. Subjects were admitted to the Clinical Research 
Center for a standardized meal the evening prior to the planned study. Two 
intravenous access lines were placed: A 20G X 3cm Teflon coated catheter in 
the antecubital vein of one arm for initial blood sampling, as well as GLP-1 and 
PET tracer infusions, and the following morning a second 20G X 3cm Teflon 
coated catheter was placed in the contralateral arm for blood sampling.  Prior to 
an overnight infusion of normal saline or GLP-1 (1.5 pmol/kg/min, iv, Bachem 
Inc., Torrance, CA, USA), subjects had venous blood samples collected for 
measurement of relevant metabolites (glucose, insulin, free fatty acids, GLP-1 (7-
36), and total GLP-1). Non-invasive measurements of hemodynamics were taken 
at the same time point using surface electrodes placed on the thorax and neck 
(impedence cardiography, CardioDynamics, San Diego, CA, USA), and an 
automated blood pressure cuff. Positron Emission Tomography (PET) 
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measurements began in the morning following an overnight (10 hrs) test infusion, 
and lasted ∼3 hours. These measurements include cardiac perfusion and 
oxidative metabolism (11C-acetate) and glucose uptake (18F-deoxyglucose) under 
resting fasting conditions. Following PET imaging, end-of-protocol blood samples 
and hemodynamic measures were taken (∼13 hrs total infusion time), and test 
infusions was terminated. 
PET modeling and analysis. Myocardial glucose uptake was calculated by 
analyzing 18F-deoxyglucose kinetics using the standard three-compartment 
model. A two-compartment model was applied to metabolite-corrected 11C-
acetate data to derive rates of cardiac perfusion (early influx kinetics) and 
myocardial oxygen consumption (MVO2) (late disappearance kinetics)(184).  
Ossbaw swine model of MetS. Lean control swine were fed ~2200 
kcal/day of standard chow (5L80, Purina Test Diet, Richmond, IN, USA) 
containing 18% kcal from protein, 71% kcal from complex carbohydrates, and 
11% kcal from fat.  MetS swine were fed an excess ~8000 kcal/day high 
fat/fructose, atherogenic diet containing 16% kcal from protein, 41% kcal from 
complex carbohydrates, 19% kcal from fructose, and 43% kcal from fat (mixture 
of lard, hydrogenated soybean oil, and hydrogenated coconut oil), and 
supplemented with 2.0% cholesterol and 0.7% sodium cholate by weight (KT324, 
Purina Test Diet, Richmond, IN, USA).  Both lean and MetS castrated male 
swine were fed their respective diets for ~16 weeks prior to surgical 
instrumentation. 
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Swine surgical instrumentation. Ossabaw swine were fasted overnight 
prior to surgical procedures. Sedation was initiated with a combination of telazol 
(5 mg/kg sc) and xylazine (2.2 mg/kg sc). Following endotracheal intubation, a 
surgical plane of anesthesia was maintained by mechanical ventilation with 1 to 
3% isoflurane supplemented with oxygen. Using sterile techniques, a left lateral 
thoracotomy was performed in the 5th intercostal space, and a catheter (17-Ga 
pressure-monitoring catheter, Edwards LifeSciences, Irvine, CA, USA) was 
implanted in the descending thoracic aorta to measure aortic blood pressure and 
heart rate, and obtain arterial blood samples. A second catheter was placed in 
the anterior interventricular vein for coronary venous blood sampling from the 
LAD perfusion territory and iv drug administration. The proximal left anterior 
descending (LAD) coronary artery was secured to a Transonics perivascular flow 
transducer (Transonic Systems, Inc., Ithaca, NY, USA) for coronary blood flow 
measurements. Catheters and the flow transducer wires were tunneled 
subcutaneously and exteriorized between the scapulae. The chest was closed in 
layers, and the pneumothorax evacuated with a chest tube using manual suction. 
Antibiotics (exceed, 5 mg/kg, im), anti-inflammatories (rimadyl, 4 mg/kg, im), and 
analgesics (buprenorphine, 0.015 mg/kg, im) were administered to prevent 
infection and manage post-operative pain. The externalized catheters/wire were 
protected with Vetrap (Animal Care Products, St. Paul, MN, USA) and custom 
made jackets. An elastomeric balloon pump with flow control tubing (MILA 
International, Erlanger, KY, USA) was connected to the coronary venous catheter 
for continuous infusion of heparinized saline (2.5 U/ml at 0.5 ml/hr), and for GLP-
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1 (7-36) administration. The aortic catheter was cleared, flushed and filled with 
heparinized saline (5 U/ml) daily.    
Swine experimental protocol and blood sampling. Following recovery from 
surgery, experiments were conducted in lean and MetS Ossabaw swine at rest 
and during graded treadmill exercise, before and during the administration of 
GLP-1 (7-36) (1.5 pmol/kg/min, iv, started 2 hrs. prior to exercise protocol). 
Importantly, each animal served as its own control. Aortic blood pressure, heart 
rate and LAD coronary blood flow were continuously recorded at rest and during 
two levels of treadmill exercise (~2 mph and ~5 mph). Each exercise period 
lasted ~2 min, and the swine were rested between bouts until hemodynamic 
parameters returned to baseline values. Baseline blood samples were collected 
before and after the 2 hrs continuous infusion of GLP-1 (7-36) for phenotypic 
profiling and measurement of plasma GLP-1. Arterial and anterior interventricular 
coronary venous samples were also simultaneously collected at rest and during 
exercise in heparinized syringes and immediately sealed and placed on ice. 
These blood samples were taken when hemodynamic variables had stabilized at 
each level and analyzed in duplicate for hematocrit, PCO2, PO2, oxygen content, 
lactate, pH and glucose with a GEM Premier 3000 blood gas analyzer and 682 
Co-oximeter system (Instrumentations Laboratories, Bedford, MA, USA). 
Myocardial oxygen consumption (MVO2, µmol O2/min/g) was calculated by 
multiplying coronary blood flow by the arterial coronary venous difference in 
oxygen content.    
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Western blot analysis. Following excision of the hearts, the coronary 
circulation was perfused with physiologic salt solution to removed blood and 
blood proteins, then crude transmural LV samples and epicardial coronary 
vessels were quickly isolated, frozen in liquid N2 and stored at -80˚C. These 
samples were later homogenized in lysis buffer, and protein was quantitated 
using a DC protein assay. 25 µg of protein was loaded onto 7% acrylamide gels, 
electrically separated and then transferred overnight onto nitrocellulose 
membranes. Membranes were blocked for one hour prior to an overnight 
incubation in primary antibody at 4˚C. Membranes were exposed to secondary 
antibodies for 1 hr at ambient temperature. Immunoreactivity and quantitation 
was determined with a Li-Cor Odyssey system (Li-Cor Biosciences, Lincoln, NE, 
USA). Intensities were normalized to that of α-actin (691002, MP Biomedicals, 
Solon, OH, USA), and band size was determined using a standard protein ladder 
(161-0375, BIO Rad, Hercules, CA, USA). Total p38-MAPK was determined with 
a p38α-MAPK antibody (9218, Cell Signaling Technologies, Boston, MA, USA), 
and GLP-1 receptor content determined using a polyclonoal antibody (ab39072, 
abcam, Cambridge, MA, USA). 
Immunohistochemistry and confocal microscopy. Fresh LV cardiac 
samples were snap frozen in liquid N2 and stored at -80˚C. The frozen samples 
were embedded in Tissue-Tek OCTTM (Sakura Finetek USA Inc, Torrance, CA, 
USA) and sliced into 10 um sections. Slices were incubated in mouse 
monoclonal antibodies against cardiac troponin I (ab10231; 1:1,000), 4’,6-
diamidino-2-phynlindole (DAPI, 100 ng/ml), and rabbit polyclonal antibodies 
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raised against GLP-1R (ab39072; 1:25) for 1 hr. Slices were subsequently 
washed and treated with anti-rabbit IgG and anti-mouse IgG secondary 
antibodies for 30 min, conjugated with alexa-488 and alexa-594 respectively. 
Slides were imaged at 20X on an Olympus2 single photon confocal microscope 
(Olympus America Inc., Center Valley, PA, USA). 
Enzyme activity assays. Fresh transmural LV tissue slices (~200 µm) from 
lean and MetS Ossabaw swine hearts were placed into preheated (37˚C) tissue 
baths of physiological salt solution and oxygenatated with 95% O2 and 5% CO2. 
The baths were then either dosed with GLP-1 (7-36) to bring the concentration to 
1 nmol/L or 5 nmol/L, or not dosed for a sham control. The tissue slices were 
incubated in these conditions for 1 hr. at which time they were quickly rinsed and 
snap frozen in liquid N2.  
The p38-MAP Kinase enzyme activity was determined using the protocol 
provided with the nonradioactive p38-MAP Kinase Assay Kit (9820, Cell 
Signaling Technologies). Briefly, frozen tissue sample were homogenized in lysis 
buffer, protein content quantitated then adjusted with the addition of lysis buffer 
to equalize protein concentrations (0.875 µg/ul). 20 µl of immobilized Phospho-
p38-MAPK (Thr180/Tyr182) primary antibody bead slurry was added to 200 µl 
protein extracts and incubated overnight at 4˚C. This mixture was then 
centrifuged to isolate the bead pellet and washed with lysis buffer and kinase 
buffer, two times each. The pellet was then suspended in 50 µl of kinase buffer 
supplemented with 200 µmol/L ATP and 1 µL ATF-2 fusion protein (kinase 
substrate), and incubated in a 30˚C water bath for 30 min. This reaction was 
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terminated with 3X SDS running buffer, heated at 95˚C for 5 min. and then 30 µl 
loaded onto 10% acrylamide gels. A biotenylated protein marker (7727, Cell 
Signaling Technology) was used to estimate molecular weights. After transferring 
to a nitrocellulose membrane, the membranes were treated with blocking buffer 
for 1 hr then incubated in Phospho-ATF-2 (Thr 71) primary antibody (1:1,000) at 
4˚C overnight. The membranes were incubated in a secondary antibodies 
conjugated with HRP at ambient temperature for 1 hr, incubated in HRP 
substrate for 3 minutes, and imaged to determine immunoreactivity. Signal 
quantitation was conducted using image J, and normalized to sham controls. 
PKA enzyme activity assays were conducted in accordance with the 
nonradioactive MESACUP® Protein Kinase Assay Kit (5230, MBL international, 
Woburn, MA). Breifly, 12 µl of protein samples (0.875 µg/µl) was added to 108 µl 
of a reaction mixture with and without supplemental cAMP (20 µmol/L) to 
determine maximal and basal activity respectively. These mixtures were 
incubated in PS-peptide coated wells in a water bath at 25˚C for 10 minutes. The 
reaction was terminated with a stop solution and the wells washed several times. 
100 µl of biotinylated antibody was then added to each well and incubated at 
25˚C for 1 hr The wells were again washed several times then treated with 100 µl 
of POD-conjugated streptavidin at 25˚C for 1 hr. After a final wash, 100 µl of 
colorimetric substrate was added for 5 minutes, and then terminated with 100 µl 
of stop solution. Optical density was measured at 492 nm, and values were 
normalized to sham controls with and without cAMP added to the reaction 
mixtures. 
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Statistical analysis. Data are presented as mean ± SE. For all statistical 
comparisons, P ≤ 0.05 was considered statistically significant. Human studies 
data were evaluated using a one-way Analysis of Variance (ANOVA) comparing 
3 groups (lean saline, lean GLP-1 and T2DM GLP-1). To compare lean to MetS 
swine, or treated to untreated swine, under the same experimental conditions 
one-way ANOVA was used. To evaluate the effects of MetS and/or GLP-1 on 
hemodynamic responses to exercise, a three-way ANOVA was used (Factor A: 
drug treatment; Factor B: exercise level; Factor C: diet). For in-vitro studies, t-
tests were conducted to determine the effect of GLP-1 within lean and MetS 
groups, and one-way ANOVA was used to compare lean to MetS groups under 
the same experimental condition. When significance was found with ANOVA, a 
Student-Newman-Keuls multiple comparison test was performed to identify 
differences between groups and treatment levels. Multiple linear regression 
analysis was used to compare slopes of response variables (myocardial glucose 
uptake) plotted vs. MVO2.  
RESULTS 
Phenotypic and hemodynamic data in resting human subjects with and 
without intravenous GLP-1. Baseline fasting phenotypic data in lean and 
MetS/T2DM human subjects differed as expected: Body Mass Index (BMI), 
plasma insulin and glucose were significantly elevated in the MetS/T2DM group 
(Table 3-1A). The Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR) was also significantly elevated in MetS/T2DM under baseline fasting 
conditions; however, non-esterified fatty acids were not significantly different 
between groups. GLP-1 (7-36) infusion (1.5 pmol/kg/min iv for ∼13 hrs) increased 
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plasma GLP-1 (7-36) concentrations equally in lean and MetS/T2DM human 
subjects by ∼15 fold. Total plasma GLP-1 concentration at baseline was elevated 
in MetS/T2DM, but was equal to that of lean controls following the ∼13 hrs of 
GLP-1 (7-36) infusion. Administration of GLP-1 plus basal insulin overnight 
significantly lowered plasma glucose in subjects with MetS/T2DM; there was no 
effect of GLP-1 on plasma glucose in lean subjects. Plasma glucose was not 
different between lean and MetS/T2DM groups following GLP-1 administration. 
Baseline resting systolic blood pressure, mean aortic pressure, and heart rate 
were significantly elevated in MetS/T2DM subjects compared to lean subjects, 
while baseline stroke volume, cardiac output, and diastolic blood pressure were 
not different (Table 3-1B). GLP-1 administration did not affect any hemodynamic 
parameter measured in either lean or MetS/T2DM human subjects. 
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Effects of GLP-1 (7-36) on myocardial blood flow, glucose uptake and total 
oxidative metabolism in lean and MetS/T2DM human subjects. Using dynamic 
positron emission tomography, we determined that iv infusion of GLP-1 (7-36) 
increased myocardial glucose uptake over 4-fold in lean subjects. However, 
myocardial glucose uptake in MetS/T2DM subjects treated with GLP-1 was 
markedly lower than GLP-1 stimulated uptake in lean subjects and no different 
from lean saline treated controls (Figures 3-1A and 3-1B). Administration of 
GLP-1 did not affect basal coronary blood flow in either group (Figure 3-1D), but 
modestly increased basal MVO2 in lean subjects (Figure 3-1C). Importantly, 
these impaired responses to GLP-1 in MetS/T2D occurred despite similar plasma 
concentrations of GLP-1 (total and 7-36), glucose, and non-esterified fatty acids, 
and despite higher circulating insulin concentrations in DM subjects (Table 3-
1A). 
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Figure 3-1   Effect of GLP-1 on myocardial glucose uptake, total oxidative 
metabolism, and blood flow in human subjects. A representative PET image 
for the effect of GLP-1 on myocardial glucose uptake in lean subjects (A). T2DM 
subjects treated with GLP-1 had myocardial glucose uptake lower than that of 
lean subjects treated with GLP-1, and not different than lean subjects given 
saline (B). Myocardial Oxygen Consumption (MVO2) was modestly elevated in 
lean subjects treated with GLP-1, but not different between lean saline control 
and MetS/T2DM + GLP-1 (C). Coronary blood flow was not different between any 
groups. GLP-1 increased myocardial glucose uptake in lean subjects (D). (‡) P ≤ 
0.05 vs. lean saline and T2DM +GLP-1; (*) P ≤ 0.05 vs. lean saline      
 
Phenotypic data in lean and MetS Ossabaw swine. In comparison to lean 
swine, high-fat fed swine had significantly elevated body weight, mean aortic 
pressure, triglycerides, cholesterol and LDL/HDL ratio. There were no differences 
between lean and MetS swine in fasting insulin, plasma glucose, or HOMA-IR; 
however, MetS swine did have hyperglucagonemia. (Table 3-2A). GLP-1 had no 
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effect on the phenotypic plasma profiles of lean or MetS swine. Fasting levels of 
total GLP-1 and GLP-1 (7-36) were not different between lean and MetS swine, 
and the average plasma concentrations increased equally in both groups 
following GLP-1 (7-36) administration (1.5 pmol/kg/min, iv, 2 hrs) (Table 3-2A). 
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Hemodynamic effects of GLP-1 (7-36) in resting and exercising swine. 
Resting systolic and mean aortic blood pressure were significantly elevated in 
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MetS swine compared to lean swine, and diastolic blood pressure tended to be 
higher in MetS swine (P = 0.057). There was no difference in resting heart rate 
between lean and MetS swine (Table 3-2B). Administration of GLP-1 had no 
effect on blood pressure or heart rate at rest or in response to exercise in lean or 
MetS swine. Furthermore, coronary blood flow and MVO2 were not different 
between lean and MetS swine at rest or during exercise, and GLP-1 had no 
significant effect on these measures in either group (Table 3-2B). 
Effects of GLP-1 (7-36) on myocardial substrate uptake in lean and MetS 
Swine. In lean swine GLP-1 stimulated a significant increase in the slope of the 
relationship between increasing MVO2 (independent variable) and myocardial 
glucose uptake during exercise (Figure 3-2A). In MetS swine, there was a 
paradoxical decrease in the slope of the relationship between myocardial glucose 
uptake and MVO2 (Figure 3-2B). Resting arterial lactate was significantly 
elevated in MetS swine compared with lean swine (Table 3-2A), and lactate 
uptake increased as a function of MVO2 in both lean and MetS swine; GLP-1 had 
no effect on this relationship (Figures 3-2C and 3-2D). 
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Figure 3-2   Effects of GLP-1 on myocardial substrate metabolism in 
exercising Ossabaw swine. GLP-1 (1.5 pmol/kg/min iv, 2 hrs) increased 
myocardial glucose uptake in response to increasing myocardial oxygen 
consumption in exercising lean (A) but not MetS (B) swine. Myocardial lactate 
uptake was not affected by GLP-1 in either lean (C) or MetS (D) swine.  
 
Myocardial and coronary expression of GLP-1R. Immunohistochemistry 
with confocal fluorescence microscopy revealed both myocardial and trans-
adventitial coronary artery expression of GLP-1R in Ossabaw swine (Figure 3-
3A). Counterstaining the tissue with 4',6-diamidino-2-phenylindole (DAPI) and 
fluorescent-linked antibodies raised against cardiac troponin I demonstrate the 
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presence of nuclei (blue) and myocardium (red) respectively, adding detail to the 
tissue architecture (Figure 3-3B). A representative western blot qualitatively 
demonstrates no difference in cardiac GLP-1R content between lean and MetS 
swine, and depicts clean immunoreactivity at the expected size band for GLP-1R 
at ∼53 kDa. The internal control α-actin is demonstrated as a band at ∼42 kDa 
(Figure 3-3C). Quantification of western blots revealed no differences between 
lean and MetS swine in the total coronary or crude cardiac GLP-1R content 
(Figure 3-3D).  
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Figure 3-3   Cardiac GLP-1R expression in Ossabaw swine. GLP-1R (green) 
was present in the myocardium and coronary microvessels of Ossabaw swine 
(A). Tissue architecture is further demonstrated (B) with the nuclear stain DAPI 
(blue) and antibodies against cardiac troponin I (red). A negative control depicts 
low tisuue auto fluorescence (C). Western Blot revealed the expected molecular 
weight bands for GLP-1R (~53 kDa) and the loading control alpha actin (~42 
kDa) in cardiac tissue from lean and MetS swine (D). There were no differences 
between lean and MetS swine in either coronary or crude cardiac GLP-1R 
expression (E). 
 
Effects of GLP-1 on cardiac PKA and p-38 MAPK enzyme activity. Basal 
and cAMP stimulated PKA activity differed as expected in untreated (sham 
control) cardiac tissue from lean swine (0.054 Abs492 at baseline vs. 1.367 Abs492 
with cAMP); however, there were no differences in basal or cAMP stimulated 
PKA activity between lean and MetS groups. Treatment of fresh cardiac tissue 
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slices with GLP-1 (7-36) (1 to 5 nmol/L) for 1 hour in a tissue bath of physiologic 
salt solution at 37˚C did not affect basal or cAMP stimulated PKA activity when 
compared to untreated sham controls in tissue from either lean or MetS swine 
(Figure 3-4).  
 
Figure 3-4   Effect of GLP-1 on cardiac PKA activity in Ossabaw swine. 
Treatment of cardiac slices with GLP-1 (1 nmol/L to 5 nmol/L) for 1 hr had no 
effect on basal PKA activity in tissue from lean and MetS swine. Addition of the 
PKA activator cAMP to the reaction mixture did not affect the relative activity 
between GLP-1 treated and untreated tissue from lean or MetS swine.         
 
A representative western blot demonstrates selective immunoreactivity 
and abundant expression of p38α-MAPK at the expected band size of ∼41 kDa. 
The band for the internal control α-actin (∼42 kDa) appears just above that of 
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p38α-MAPK (Figure 3-5A). Total p38α-MAPK content was not different in 
cardiac tissue from lean or MetS swine (Figure 3-5B). Enzymatic activity of p38-
MAPK in cardiac tissue from lean and MetS swine treated with saline (sham) or 
GLP-1 (7-36) is demonstrated with immunoreactivity to the p38-MAPK product 
phosopho-ATF-2 (∼34 kDa) (Figure 3-5C). MAPK activity dose-dependently 
increased in response to GLP-1 administration in cardiac tissue from lean swine. 
In contrast, p38-MAPK activity was markedly diminished in hearts from MetS 
swine under control conditions and was unchanged by GLP-1 administration 
(Figure 3-5D).  
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Figure 3-5   Effect of GLP-1 on cardiac p38-MAPK activity in Ossabaw 
swine. A representative image of total cardiac p38α-MAPK from lean and MetS 
swine (A). There was no difference in total cardiac expression of p38α-MAPK 
between lean and MetS swine (B). A representative image from the enzyme 
activity assay demonstrates differential presence of the p38-MAPK product 
Phospho-ATF-2 (~ 34 kDa) (C).Treatment of cardiac slices with GLP-1 (1nmol/L 
to 5 nmol/L) for 1 hr increased p38-MAPK activity in tissue from lean but not 
MetS swine, and activity was lower in tissue from MetS swine at all levels of 
treatment (D). (*) P ≤ 0.05 vs. lean sham; (†) P ≤ 0.05 vs. lean same condition  
  
Discussion 
This investigation was designed to examine the cardiovascular effects of 
GLP-1 in the setting of the MetS and T2DM. The major novel findings from these 
translational studies in T2DM humans and obese swine were: 1) GLP-1 
administration had no effect on blood pressure, heart rate, or coronary blood flow 
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at rest or during exercise-induced increases in MVO2 in lean or obese/T2DM 
subjects; 2) GLP-1-mediated increases in myocardial glucose uptake are 
significantly diminished in obesity/MetS and T2DM; 3) impaired myocardial 
responsiveness to GLP-1 is not associated with alterations in GLP1R expression 
or activation of cAMP/PKA signaling; 5) GLP-1 dose-dependently activates p38-
MAPK in normal-lean, but not obese/MetS hearts. Taken together, these findings 
indicate that the potential cardioprotective effects of GLP-1 on myocardial 
glucose metabolism are attenuated in obesity and T2DM via reductions in p38-
MAPK activity. 
Effects of GLP-1 on systemic hemodynamics, cardiac function, and 
coronary blood flow. Heart rate, blood pressure, cardiac output, and stroke 
volume were not affected by GLP-1 administration in either lean or MetS/T2DM 
human subjects (Table 3-1B). In swine, heart rate and blood pressure were also 
unaffected by GLP-1 at rest and during exercise (Table 3-2B). Numerous 
investigations have demonstrated that iv GLP-1 increases cardiac output, stroke 
volume, and other parameters of left ventricular performance in the settings of 
ischemia-reperfusion injury and/or heart failure (87-90, 94, 98, 110). However, 
our present findings indicate that GLP-1 does not affect systemic hemodynamics 
or left ventricular performance in the non-injured/non-failing heart.  
We also found that systemic administration of GLP-1 had no effect on 
coronary blood flow in lean vs. T2DM humans (Figure 3-1D), or in lean vs. 
obese/MetS swine (Table 3-2B). Previous data regarding the effects of GLP-1 on 
coronary blood flow have been equivocal, as intracoronary GLP-1 (7-36) has 
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been reported to increase perfusion in isolated rodent hearts (91, 93) but have no 
effect in-vivo in canines (185). Most studies examining the effects of intravenous 
GLP-1 on coronary blood flow in canines and swine also report no vasodilator 
effect (94, 110, 133). However, one study that reported a modest yet significant 
increase in coronary flow also found that GLP-1 increased MVO2; i.e. increase is 
coronary blood flow was likely the result of metabolic dilation, not vasodilation in 
response to GLP-1 (89). These findings are consistent with previous data from 
our laboratory, which showed no effect of GLP-1 (10 pmol/L to 1 nmol/L) on 
isolated intact or endothelium denuded coronary arteries (185).  
Effects of GLP-1 on myocardial substrate metabolism in MetS/T2DM. The 
major findings of this study demonstrate that the cardiac action of iv GLP-1 to 
increase myocardial glucose uptake is significantly attenuated in obesity/MetS 
and T2DM (Figures 3-1A, 3-1B, 3-2A and 3-2B). This impaired cardiometabolic 
response to GLP-1 is clinically significant because augmented myocardial 
glucose uptake is indicated as an important mechanism by which GLP-1 protects 
the heart from injury/infarction (53, 89, 91, 93, 110). Importantly, this attenuated 
response in MetS-T2DM is not related to differences in plasma GLP-1 
concentration (Tables 3-1A and 3-2A). Furthermore, similar plasma 
concentrations of glucose and NEFA in humans also indicate that the impaired 
response to GLP-1 is not related to alterations in plasma substrate availability 
(Table 3-1A). Although this study indicates no effect of GLP-1 on myocardial 
lactate uptake (Figure 3-2C and 3-2D), alterations in other substrates (i.e. free 
fatty acids) is needed; elevated myocardial glucose uptake in lean subjects vs. 
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MetS/T2DM with a post-treatment MVO2 that is not different (Figure 3-1C and 
Table 3-2B), suggest iv GLP-1 decreases cardiac free fatty acid utilization in lean 
but not MetS/T2DM subjects.  
Potential mechanisms for impaired cardiometabolic effects of GLP-1 in 
MetS/T2DM. To uncover potential mechanisms underlying the impaired 
cardiometabolic responses to GLP-1 in the setting of MetS and T2DM, we 
examined coronary and myocardial GLP-1R expression, as well as PKA and 
p38-MAPK activity. Our immunohistochemistry studies confirm GLP-1R 
expression in both myocardium and the coronary vasculature (Figures 3-3A and 
3-3B). Importantly, Western blot analysis revealed no difference in coronary or 
myocardial GLP-1R content between lean and MetS swine, suggesting the 
impaired responses to GLP-1 in MetS are not mediated by a decrease in total 
GLP-1R expression (Figures 3-3C and 3-3D).  
Previous investigations indicate that the myocardial effects of GLP-1 are 
mediated via activation of cAMP/PKA and/or p38-MAPK signaling pathways (91, 
93, 94, 101, 182). To examine potential effects on each of these pathways, we 
performed studies on myocardial tissue slices exposed to either sham-vehicle or 
GLP-1 (1 nmol/L or 5 nmol/L). We found no differences in basal or cAMP 
stimulated cardiac PKA activity between lean and MetS swine, and treatment 
with GLP-1 had no effect on PKA activity in either group (Figures 3-4). These 
data are consistent with the lack of effect of GLP-1 to increase cardiac contractile 
function in normal hearts (Table 3-1B; (91, 185)) and also argues against a role 
for GLP-1 in activating classical inotropic (β-adrenergic) signaling pathways. In 
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contrast however, we did find that GLP-1 dose-dependently increased p38-
MAPK activity in lean-control hearts (Figure 3-5C and 3-5D). Importantly, no 
differences in the overall level p38α-MAPK expression were detected in lean vs. 
MetS swine hearts; i.e. total cardiac p38-MAPK expression levels were not 
affected by MetS (Figure 3-5A and 3-5B).  Interestingly, basal p38-MAPK 
activity was significantly lower in cardiac tissue from MetS swine, and did not 
respond to treatment with GLP-1 (Figures 3-5C and 3-5D). These data indicate 
that the cardiometablic effects of GLP-1 are mediated by a non-classical GLP-1 
signaling pathway involving p38-MAPK, and not cAMP/PKA. This finding is 
supported by previous investigations in canines demonstrating that p38-MAPK 
activity is increased in response to GLP-1 treatment, and that inhibition of p38-
MAPK abolished the effect of GLP-1 to increase myocardial glucose uptake. 
Conclusion 
Data from this investigation provide novel evidence that the myocardial 
effect of GLP-1 to increase glucose uptake is impaired in the settings of MetS 
and T2DM in association with defects in p38-MAPK signaling. These findings are 
significant because drug therapies used to increase myocardial glucose uptake 
have been targeted as potential treatment and management of heart disease for 
decades (52, 57, 112, 113, 116, 118, 122, 186, 187). Previous investigations 
have demonstrated that GLP-1 based therapies are useful in protection from and 
treatment of cardiac injury/failure (87-94, 97, 98, 100-102, 104-107, 140, 180, 
188-190), and increases in glucose metabolism are believed to play a key role in 
these clinical outcomes (89, 91, 93, 94, 110, 185). Currently GLP-1 based 
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therapies are widely used for glycemic control in patients with T2DM (179, 191, 
192), and our results indicate that the effects of GLP-1 to reduce cardiac damage 
and increase left ventricular performance in the settings of ischemia/reperfusion 
injury and heart failure may be impaired by MetS and T2DM. However, future 
studies are needed to examine if the cardiometabolic deficit translates into a 
cardioprotective deficit. If the defect in glucose response equates to a defect in 
cardioprotective actions, strategies to overcome this impaired action and improve 
the beneficial cardiac effects of GLP-1 to patients with MetS/DM will be needed. 
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Chapter 4 
Discussion 
As the prevalence of obesity, MetS and T2DM continue to rise, there is an 
imminent health-care need to develop new therapeutic strategies to address the 
heightened incidence of cardiovascular morbidity and mortality in these patient 
populations (1, 4, 10, 147-149). While reasons for an increased incidence of 
adverse cardiac events and outcomes in these populations are still active areas 
of investigation, coronary microvascular dysfunction and diminished cardiac 
glucose metabolism have been implicated as common underlying morbidities 
(11, 13, 14, 17-20, 22, 26, 27, 29, 33, 40, 43, 53-56).  Thus, improving 
myocardial oxygen delivery and promoting more efficient cardiac substrate 
utilization; i.e. restoring the balance of myocardial oxygen supply and demand, 
are primary targets for advancing the treatment and management of obesity-
related cardiovascular disease (14, 20, 26, 53, 150-152).  
Recent advancements in the management of systemic glucose regulation 
in obesity/T2DM include drug therapies designed to utilize components of the 
incretin system specifically related to glucagon-like peptide 1 (GLP-1) (169, 173, 
174, 193-195). More recently, GLP-1 has been investigated for potential 
cardioprotective effects. Several investigations have revealed that intravenous 
administration of GLP-1 significantly reduces myocardial infarct size following 
ischemia/reperfusion injury and improves cardiac contractile function in the 
settings of coronary artery disease, myocardial ischemia/reperfusion injury, and 
heart failure (87-90, 94, 98, 110, 180, 181). While the mechanisms responsible 
for these effects of GLP-1 are still under investigation, increases in myocardial 
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glucose uptake and coronary blood flow via a p38 MAPK and/or PKA dependent 
signaling pathway have been implicated (91, 93, 94, 101, 182). 
Despite an abundance of data indicating that intravenous infusion of GLP-
1 is cardioprotective, information has been lacking on the cardiac effects of iv 
GLP-1 in the MetS or T2DM population. It was recently recognized that the 
insulinotropic effect of GLP-1 is diminished, although still effective, in the setting 
of obesity/T2DM (95). However, whether obesity, MetS, and/or T2DM alter the 
cardiac actions of GLP-1 has not been directly evaluated. Thus, while GLP-1 
may be useful in the treatment and management of obesity related heart disease 
by improving coronary microvascular function and myocardial glucose uptake, 
there is a distinct possibility that the cardiac actions of GLP-1 are impaired in the 
settings of obesity/MetS and T2DM.  
Some important questions this study aimed to address are 1) what are the 
direct, dose-dependent cardiac effects of GLP-1 in-vivo 2) are the cardiac effects 
influenced by cardiac demand (MVO2) and/or ischemia, 3) does GLP-1 effect 
myocardial blood flow, glucose uptake or total oxidative metabolism in human 
subjects, and 4) are the cardiac effects of GLP-1 treatment impaired in the 
settings of obesity/MetS and T2DM.  
In an effort to address these questions we conducted translational studies in 
open-chest canines, our novel Ossabaw swine model of obesity/MetS, human 
subjects with MetS/T2DM, as well as lean swine and human subjects. The major 
objectives of this study were to more fully elucidate the cardiac actions of GLP-1, 
determine if these actions are impaired in the setting of obesity/MetS, and 
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uncover potential mechanisms of impairment. These objectives were met by 
pursuing the following Specific Aims: 
Aim 1: Determine the acute, dose-dependent cardiac effects of 
intracoronary GLP-1 under conditions of normal coronary perfusion and 
during ischemia. Initial studies conducted in canines demonstrated that GLP-1 
had no direct effect on coronary blood flow in-vivo or vasomotor tone in-vitro, but 
preferentially increased myocardial glucose uptake in ischemic myocardium 
independent of effects on cardiac contractile function or coronary blood flow.   
Aim 2: Test the hypothesis that obesity/MetS impairs the cardiac responses 
to GLP-1, and investigate potential mechanisms of such impairment. 
Parallel translational studies conducted in the humans and Ossabaw swine 
demonstrate that iv GLP-1 significantly increases myocardial glucose uptake at 
rest and in response to increases in cardiac demand (MVO2) in lean subjects, but 
not in the settings of obesity/MetS and T2DM. Further investigation in isolated 
cardiac tissue from lean and obese/MetS swine indicate that this impairment in 
GLP-1 responsiveness is related to attenuated activation of p38-MAPK, 
independent of alterations in GLP-1 receptor expression or PKA-dependent 
signaling. 
Implications 
We have produced the first evidence for impaired cardiometabolic 
responses to GLP-1 in obesity, MetS and T2DM (Figures 3-1A, 3-1B, 3-2A and 
3-2B). Results from this study indicate that the impairment in GLP-1 
responsiveness is related to attenuated activation of p38-MAPK (Figure 3-5C 
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and 3-5D), and is independent of alterations in coronary blood flow (Figure 3-1D 
and Table 3-2B), GLP-1 receptor expression (Figure 3-3), and PKA-dependent 
signaling (Figure 3-4). 
Coronary vascular effects of GLP-1. Our findings demonstrate that although 
GLP-1R is expressed in the coronary vasculature (Figures 2-1 and 3-3), 
administration of GLP-1 does not increase coronary blood flow in canines 
(Figure 2-2), swine (Table 3-2B) or humans (Figure 3-1B). These data are in 
contrast with earlier studies which documented that GLP-1 induces vasodilation 
in isolated arteries, increases coronary blood flow in isolated hearts under normal 
conditions and during reperfusion, and following pacing induced cardiomyopathy 
in canines. However, such previous studies were conducted in aorta (130, 132), 
femoral (129), and pulmonary vessels (131), isolated rodent hearts (91, 93), and 
with systemic administration of recombinant GLP-1 (7-36) in canines (89).  It is 
also important to recognize that the increased coronary blood flow previously 
documented in-vivo in canines was accompanied by increases in cardiac 
contractile function and MVO2, the primary determinants of coronary flow; i.e. 
metabolic vasodilation. Other studies conducted in this same canine model, and 
by the same laboratory, demonstrated no effect of GLP-1 on MVO2 or coronary 
blood flow (94, 110). The reasons for the discrepant findings regarding the 
vascular effects of GLP-1 are unclear but are likely related to differences in 
specific vessels studied, species investigated, in-vivo vs. in-vivo experimental 
conditions. Regardless, our findings provide strong evidence that neither acute 
administration of physiologic/pharmacologic concentrations of GLP-1 directly in 
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to the coronary circulation, nor longer-term iv GLP-1 administration influence 
coronary blood flow.  
Effects of GLP-1 on hemodynamics and cardiac function. This investigation 
revealed no effect of iv GLP-1 on heart rate, blood pressure, stroke volume or 
cardiac output in lean or MetS/T2DM human subjects at rest (Tables 3-1B and 
3-2B). We also observed no effect of iv GLP-1 on heart rate or blood pressure 
during exercise induced increases in cardiac demand (Table 3-2B). Several 
previous investigations have reported that GLP-1 increases indices of LV 
function (i.e. developed pressure, wall thickening, dP/dt and ejection fraction) 
during reperfusion, heart failure and dilated cardiomyopathy (87-92, 94, 98, 99, 
101-103, 110, 140, 180, 181). However, our present findings indicate that GLP-1 
does not effect systemic hemodynamics or left ventricular performance in the 
non-injured/non-failing heart. 
 We also observed no direct effect of acute intracoronary GLP-1 (7-36) 
infusion on indices of regional or global cardiac contractile function during 
ischemia (Table 2-1 and Figure 2-4). This finding is in contrast to our hypothesis 
that increases in glucose metabolism would improve contractile function in 
ischemic myocardium, as glucose has a high P/O ratio (ATP produced per 
oxygen consumed, (53, 118) and earlier data support that increased myocardial 
glucose metabolism improves cardiac efficiency during ischemia. In particular, 
previous studies from our group documented that insulin-mediated increases in 
myocardial glucose metabolism significantly improve regional cardiac function in 
ischemic canine hearts (CPP = 40 mmHg) (52, 57). However, the increase in 
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myocardial glucose uptake induced by insulin in these studies (~0.50 
mmol/min/g) was substantially higher than that reported in the present study 
(~0.20 µmol/min/g). A longer infusion duration of GLP-1 (500 to 1000 pmol) may 
be necessary to obtain greater cardiac glucose uptake and improved left 
ventricular function.    
Interestingly, we did observe a moderate dose-dependent decrease in 
stroke volume and cardiac output at normal perfusion pressure (CPP = 100 
mmHg), without corresponding changes in dP/dt or aortic pressure (Table 2-1). 
This reduction in cardiac output was associated with an ~ 10 beats/min increase 
in heart rate.  Although there were no changes in dP/dt in our experiments, the 
reductions in stroke volume and cardiac output suggest GLP-1 reduced 
contractile performance. This observation is supported by a previous study in 
which recombinant GLP-1 (7-36) decreased LV developed pressure and dP/dt 
when infused into the coronary circulation of isolated rat hearts (91). Taken 
together, these findings indicate that acute direct (intracoronary) effects of GLP-1 
on cardiac function in undamaged hearts differ from indirect (peripheral/central) 
effects, or effects observed in the settings of heart failure, ischemia, and 
reperfusion injury.  
Cardiometabolic effects of GLP-1. The major findings of this study demonstrate 
that several hours of iv GLP-1 markedly increase myocardial glucose uptake in 
resting lean human subjects (Figure 3-1A and 3-1B), and that shorter durations 
of iv administration and acute intracoronary administration are sufficient to 
increase myocardial glucose uptake under conditions of cardiac stress (i.e. 
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increased cardiac demand (MVO2) and ischemia, Figures 3-2 and 2-5). This 
finding is consistent with previous data indicating that GLP-1 augments 
myocardial glucose uptake under conditions of cardiac stress (e.g. 
ischemia/reperfusion injury, dilated cardiomyopathy) (89, 91, 110). Also 
consistent with previous investigations, the current study revealed little to no 
effect of GLP-1 on MVO2 at rest (89, 94, 110), and extending this, there was no 
effect on MVO2 during ischemia or exercise (Figures 2-5A, 3-1C, and Table 3-
2B). Importantly, data from this investigation are the first to demonstrate that 
myocardial glucose uptake was not augmented with GLP-1 in the conditions of 
obesity/MetS or T2DM relative to lean and saline control groups (Figures 3-1 
and 3-2). Furthermore, this investigation demonstrated dose dependence for the 
cardiac insulinomemetic effect of GLP-1 in the open-chest canine experiments 
(Figure 2-5). Our results indicate that systemic administration of GLP-1 is not 
mandatory for the insulinomimetic effect to be manifest and argue against 
peripheral/central actions of GLP-1 driving alterations in substrate metabolism. 
Studies conducted in the Shannon laboratory indicate that the effects of GLP-1 
on myocardial glucose uptake occuring with several hours of iv exposure are 
mediated by GLP-1 (9-36), are dependent on p38-MAPK signaling, and occur in 
the absence of alterations in adenylate cyclase activity (94, 110). However, 
whether the acute effects of GLP-1 (7-36) on ischemic myocardial glucose 
metabolism are dependent on GLP-1R activation and/or actions of the (9-36) 
degradation product merits further investigation. A proposed mechanism by 
which GLP-1 increases myocardial glucose uptake is presented in Figure 4-1. 
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Figure 4-1   Proposed signaling mechanisms by which GLP-1 increases 
myocardial glucose uptake. GLP-1 can increase myocardial membrane content 
of both GLUT-1 and GLUT-4. Data indicate a mechanism dependent on NO and 
p38-MAPK, but independent of cAMP/PKA. GLP-1 (9-36) has been 
demonstrated to augment myocardial glucose uptake, indicating a GLP-1R 
independent pathway (91, 94, 110). 
 
Clinical Implications and Future Direction 
The impaired action of GLP-1 to increase myocardial glucose uptake in 
the settings of MetS and T2DM is clinically significant because drug therapies 
used to increase myocardial glucose uptake have been targeted as potential 
agents in the treatment and management of heart disease for decades (52, 57, 
112, 113, 116, 118, 122, 186, 187). Previous investigations have demonstrated 
that GLP-1 based therapies are useful in improving cardiac function and reducing 
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infarct size in the settings of cardiac injury/failure (87-94, 97, 98, 100-102, 104-
107, 140, 180, 188-190), and increases in glucose metabolism are believed to 
play a key role in these clinical outcomes (89, 91, 93, 94, 110, 185). Currently 
GLP-1 based therapies are widely used for glycemic control in patients with 
T2DM (196-198) and our results indicate that the effects of GLP-1 to reduce 
cardiac damage and increase left ventricular performance may be impaired by 
obesity/MetS and T2DM.  
Future studies will be useful in further defining the effects of GLP-1 on 
cardiac substrate metabolism, and determining if the cardiometabolc deficit 
(impaired myocardial glucose uptake) observed in MetS/T2DM translates into a 
cardioprotective deficit. It still remains unclear if the changes in myocardial 
glucose uptake are accompanied by alterations in fatty acid utilization. Triple 
tracer PET studies to examine the effects of GLP-1 on myocardial glucose 
uptake, fatty acid utilization, and total oxidative metabolism in combination would 
be useful in further detailing shifts in cardiac substrate utilization. Such studies 
conducted in control settings and following ischemia/reperfusion in lean and 
obese MetS Ossabaw swine can be used to detail dynamic shifts in cardiac 
substrate metabolism resulting from ischemic damage, GLP-1 and obesity/MetS, 
as well as determining infarct size. This would also address the underlying 
question of whether or not impaired responses to the cardiac insulinomemetic 
effects GLP-1 are translated into a cardioprotective deficit, and if alterations in 
glucose uptake are associated with shifts in fatty acid utilization. Figure 4-2 
	  
	  
88	  
schematically outlines a similar longitudinal study that we conducted in a 
separate investigation.   
 
Figure 4-2   Imaging modalities demonstrating the feasibility of a 
longitudinal study on the cardiac effects of GLP-1. Left panels show 
angiography demonstrating coronary anatomy and experimental balloon 
occlusion of the left circumflex coronary artery (bottom left panel, 45 min 
occlusion). Center panels show M-mode transthoracic ultrasound demonstrating 
profound wall motion abnormalities following occlusion of the coronary artery. 
Right panels show 11C-palmitate PET image demonstrating clear and readily 
quantifiable region of ischemia induced by focal occlusion (bottom right panel). 
 
If the defect in glucose response equates to a defect in cardioprotective 
actions, strategies will need to be developed to overcome this impaired action 
and improve the beneficial cardiac effects of GLP-1 to patients with MetS/T2DM. 
However, this interdependence of effects has not been demonstrated and it is 
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possible that GLP-1 exerts protective effects distinct from those relating to 
glucose uptake. 
Previous investigations have revealed that GLP-1 (9-36) has similar 
cardiac action as GLP-1 (7-36), thus indicating that the salutary cardiac actions 
of GLP-1 are in part mediated by GLP-1R independent mechanisms (110). The 
current investigation indicates that the conditions of obesity/MetS and T2DM 
render cardiometabolic resistance to both (or either) compound, as both total 
GLP-1 and GLP-1 (7-36) were elevated equally in lean vs. MetS-T2DM subjects 
following iv infusion of GLP-1 (7-36) (Tables 3-1A and 3-2A). However, further 
investigation into the cardiac actions of iv GLP-1 (9-36) in humans as well as 
large animal models should be pursued because common gastrointestinal side 
effects of GLP-1 are likely mediated by receptor dependent mechanisms. Longer 
iv infusion times of GLP-1 (7-36) allow the plasma concentration to become 
elevated to therapeutic levels gradually, and may decrease the incidence of 
nausea. Thus, the clinical implications for iv GLP-1 (9-36) may be superior to that 
of GLP-1 (7-36) as higher doses could potentially be administered, due to greater 
patient tolerance, and therapeutic plasma concentrations could be reached in a 
shorter time frame.  
Further investigation into the mechanism by which GLP-1 increases 
myocardial glucose uptake is also warranted. The current investigation, in 
agreement with previous studies, demonstrated that intracoronary infusion of 
GLP-1 at concentrations of 500 to 1000 pmol acutely (within a few minutes) 
increases myocardial glucose uptake (91, 93, 185). There is evidence indicating 
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that GLP-1 can acutely increase myocardial glucose uptake by a mechanism 
involving GLUT-1 and not GLUT-4, and that this is mediated by nitric oxide and 
p38-MAPK (91, 94). There is also evidence that GLP-1 acutely increases both 
GLUT-1 and GLUT-4 in post-ischemic myocardium with the same cellular 
signaling events involving nitric oxide and p38-MAPK (91). Thus the effects of 
GLP-1 on GLUT-4 have previously been demonstrated to be conditional, and this 
is in agreement with the current study demonstrating that acute intracoronary 
GLP-1 preferentially increased myocardial glucose uptake in ischemic 
myocardium of canines (185). However, the effects of MetS and T2DM on GLP-1 
mediated GLUT regulation has not been examined.  
In order to examine the effects of GLP-1 on GLUT regulation in more 
detail, myocardial tissue slices from lean vs. MetS swine can be exposed to GLP-
1 (7-36) or GLP-1 (9-36) without and with inhibitors of GLP-1R (exendin (9-39)) 
and p38-MAPK (SB202190). Sucrose gradient centrifugation can then be used to 
generate tissue fractionation and determine changes in GLUT-1/GLUT-4 
distribution. These same techniques could be used to examine fatty acid 
transporters. Furthermore, possible defects in the ability of GLP-1 to trans-
activate other pathways of intracellular fuel sensing and metabolic control can be 
examined in parallel, including AMPK, ACC, MCD, CPT-1, PFK, and PDK.  
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